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Background: Two antiplatelet agents are better than one for preventing recurrent stroke after acute
ischaemic stroke or transient ischaemic attack (TIA). Therefore, intensive treatment with three agents might
be better still, providing it does not cause undue bleeding.
Objective: To compare the safety and efficacy of intensive therapy with guideline antiplatelet therapy for
acute ischaemic stroke and TIA.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
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ABSTRACT
viiiDesign: International prospective randomised open-label blinded end-point parallel-group superiority
clinical trial.
Setting: Acute hospitals at 106 sites in four countries.
Participants: Patients > 50 years of age with acute non-cardioembolic ischaemic stroke or TIA within
48 hours of ictus (stroke).
Interventions: Participants were allocated at random by computer to 1 month of intensive (combined
aspirin, clopidogrel and dipyridamole) or guideline (combined aspirin and dipyridamole, or clopidogrel
alone) antiplatelet agents, and followed for 90 days.
Main outcome measures: The primary outcome was the incidence and severity of any recurrent stroke
(ischaemic, haemorrhagic; assessed using the modified Rankin Scale) or TIA within 90 days by blinded
telephone follow-up. Analysis using ordinal logistic regression was by intention to treat. Other outcomes
included bleeding and its severity, death, myocardial infarction (MI), disability, mood, cognition and quality
of life.
Results: The trial was stopped early on the recommendation of the Data Monitoring Committee after
recruitment of 3096 participants (intensive, n = 1556; guideline, n = 1540) from 106 hospitals in four
countries between April 2009 and March 2016. The incidence and severity of recurrent stroke or TIA
did not differ between intensive and guideline therapy in 3070 (99.2%) participants with data [93 vs.
105 stroke/TIA events; adjusted common odds ratio 0.90, 95% confidence interval (CI) 0.67 to 1.20;
p = 0.47]. Major (encompassing fatal) bleeding was increased with intensive as compared with guideline
therapy [39 vs. 17 participants; adjusted hazard ratio (aHR) 2.23, 95% CI 1.25 to 3.96; p = 0.006]. There
were no differences between the treatment groups in all-cause mortality, or the composite of death,
stroke, MI and major bleeding (aHR 1.02, 95% CI 0.77 to 1.35; p = 0.88).
Limitations: Patients and investigators were not blinded to treatment. The comparator group comprised
two guideline strategies because of changes in national guidelines during the trial. The trial was stopped
early, thereby reducing its statistical power.
Conclusions: The use of three antiplatelet agents is associated with increased bleeding without any
significant reduction in recurrence of stroke or TIA.
Future work: The safety and efficacy of dual antiplatelet therapy (combined aspirin and clopidogrel)
versus aspirin remains to be defined. Further research is required on identifying individual patient response
to antiplatelets, and the relationship between response and the subsequent risks of vascular recurrent
events and bleeding complications.
Trial registration: Current Controlled Trials ISRCTN47823388.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 48.
See the NIHR Journal Library website for further project information. The Triple Antiplatelets for Reducing
Dependency after Ischaemic Stroke (TARDIS) vanguard phase was funded by the British Heart Foundation
(grant PG/08/083/25779, from 1 April 2009 to 30 September 2012) and indirect funding was provided
by the Stroke Association through its funding of the Stroke Trials Unit, Division of Clinical Neuroscience,
University of Nottingham, Nottingham, UK. There was no commercial support for the trial and antiplatelet
drugs were sourced locally at each site. The trial was sponsored by the University of Nottingham.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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B rain damage due to a blood clot (stroke) is a common cause of disability in older adults. Mini-strokesare temporary damage to the brain that usually leave no long-term effect. Following a stroke or
mini-stroke, there is an increased risk of having another one, especially over the next few hours. The risk
of having another event can be reduced with blood-thinning drugs that reduce the formation of blood
clots (e.g. aspirin, clopidogrel, dipyridamole). Typically, these are used alone (clopidogrel) or in combination
(aspirin and dipyridamole). As one or two blood-thinning drugs are effective at reducing the risk of having
another stroke, intensive treatment with all three might be even more beneficial, providing that excessive
bleeding does not occur as a result.
The Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial recruited patients
who could start treatment within 48 hours of a stroke or brief mini-stroke caused by a blood clot blocking
a blood vessel. Participants were randomised (‘put into groups using chance’) to either intensive treatment
with combined aspirin, clopidogrel and dipyridamole, or routine treatment; these treatments were given
for 30 days, after which routine treatment was taken. The main result was the occurrence of a repeat
stroke or mini-stroke, and how severe they were, by 90 days. The key safety outcome was a count of
bleeds (because of blood-thinning drugs) and their severity.
The trial was stopped early on the recommendation of the Data Monitoring Committee after recruitment
of 3096 participants from 106 hospitals in four countries. Although there was no difference in the number
and severity of repeat strokes and mini-strokes between the treatment groups, serious or fatal bleeding
was increased in the group of participants receiving three blood-thinning drugs. There were no differences
between the treatment groups in the number of deaths.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
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Stroke is devastating to patients, carers and society through high mortality, morbidity and cost. Both stroke
incidence and prevalence will increase as the UK population ages. Following stroke or transient ischaemic
attack (TIA), the risk of recurrence is high, especially immediately after the event after which it falls. Typically,
recurrent strokes are more severe than earlier events.
The archetypal antiplatelet, aspirin, reduces recurrence by 17% in patients with prior stroke or TIA.
Clopidogrel is slightly more efficacious than aspirin, especially in high-risk patients. Dipyridamole reduces
recurrence with comparable efficacy to aspirin. The combination of aspirin and dipyridamole is more
effective than either drug alone.
In acute cerebral ischaemia, aspirin is effective, but two agents may be superior, as shown in a large
Chinese trial of combined aspirin and clopidogrel (Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al.
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–19),
and a meta-analysis of this and other smaller trials involving this combination, and aspirin and dipyridamole
(Wong KS, Wang Y, Leng X, Mao C, Tang J, Bath PM, et al. Early dual versus mono antiplatelet therapy for
acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and
meta-analysis. Circulation 2013;128:1656–66).
The Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial was designed to
extend this observation by investigating the safety and efficacy of intensive antiplatelet treatment with
three drugs as compared with guideline therapy.Objectives
The main objective was to compare the safety and efficacy of intensive versus guideline antiplatelet therapy
for participants with acute ischaemic stroke and TIA. A second objective was to test and demonstrate the use
of ordinal trial outcomes, including recurrent stroke and TIA, bleeding, and adverse events.Methods
The TARDIS trial was an international prospective randomised open-label blinded end-point superiority
clinical trial.
Setting
The trial enrolled patients from 106 hospitals in the UK, Denmark, Georgia and New Zealand.
Participants
Participants were > 50 years of age with acute non-cardioembolic ischaemic stroke or TIA within 48 hours
of ictus (or 24–48 hours if they had received thrombolysis). Participants with a TIA had to score ≥ 4 on the
ABCD2 scale [which takes account of age (A), blood pressure (B), clinical symptomology (C), duration of
symptoms (D), and presence of diabetes (D)], already be on two antiplatelet agents, or have a crescendo
TIA. Those with an ischaemic stroke had to have one or more of limb weakness, dysphasia or hemianopia.
Patients were excluded if they had isolated sensory or vertiginous symptoms (or only facial weakness),
intracranial haemorrhage or presumed cardioembolic cerebral ischaemia.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
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xxiiRandomisation
Participants were allocated at random to 1 month of antiplatelet agents comparing intensive (combined
aspirin, clopidogrel and dipyridamole) versus guideline therapy.
Interventions
Originally, the guideline therapy comprised the combination of aspirin and dipyridamole, but clopidogrel
alone was added following a change in National Institute for Health and Care Excellence (NICE) guidance
in 2010 [NICE. Clopidogrel and Modified Release Dipyridamole for the Prevention of Occlusive Vascular
Events. Technology Appraisal Guidance (TA210). London: NICE; 2010]. Aspirin and clopidogrel were each
given as a loading dose (300 mg) followed by maintenance doses (75 mg daily). Modified-release
dipyridamole was recommended (200 mg twice daily). Gastroprotection was recommended.
Outcomes
The primary efficacy outcome was the incidence and severity of any recurrent stroke [ischaemic,
haemorrhagic; severity determined using the modified Rankin Scale (mRS)] or TIA at 90 days, and assessed
using a six-level ordered categorical scale: fatal stroke, severe stroke (mRS score of 4–5), moderate stroke
(mRS score of 2–3), mild stroke (mRS score of 0–1), TIA or no cerebral ischaemic event. Analysis used
ordinal logistic regression and was by intention to treat. Secondary efficacy outcomes included disability,
cognition, health-related quality of life, mood and discharge disposition. The main safety outcome
was bleeding comprising a five-level ordered categorical scale: fatal, major, moderate, minor and no
bleeding. Additional safety outcomes included all-cause and cause-specific case fatality, early neurological
deterioration and serious adverse events. The net balance between efficacy and hazard was assessed as
the composite end points of any stroke or major (including fatal) bleeding and death, stroke, myocardial
infarction (MI) or major bleeding.
Sample size
Using an ordinal rather than binary outcome, and including TIA along with stroke, meant that the sample
size could be reduced from > 8000 participants to 4100, assuming an overall type I error rate of 5% with
two-sided significance test, power 90%, odds ratio of 0.68, treatment crossovers 5%, losses to follow-up
2% and a reduction of 20% for baseline covariate adjustment.Results
The trial was stopped early on the recommendation of the Data Monitoring Committee after recruitment
of 3096 participants (intensive, n = 1556; guideline, n = 1540) from 106 hospitals in four countries
between April 2009 and March 2016. The advice to stop was based on three observations: (1) the
presence of a significant increase in major bleeding in participants randomised to intensive antiplatelet
therapy, (2) the absence of a significant reduction in the primary outcome and (3) a conditional power
analysis suggested that the trial was highly unlikely to demonstrate a significant difference in the primary
outcome. Baseline characteristics were well balanced between the two treatment groups.
Primary outcome
The incidence and severity of recurrent stroke or TIA did not differ between intensive and guideline
therapy [adjusted common odds ratio (acOR) 0.90, 95% confidence interval (CI) 0.67 to 1.20; p = 0.47].
Safety outcomes
Major (encompassing fatal) bleeding increased with intensive as compared with guideline therapy (adjusted
hazard ratio (aHR) 2.23, 95% CI 1.25 to 3.96; p = 0.006) and the difference only developed during the
active treatment phase. Headache, by day 35, was more common in participants receiving intensive
antiplatelets (aHR 4.13, 95% CI 2.09 to 8.15; p < 0.001).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Length of stay in hospital, discharge disposition, dependency, disability, cognition, quality of life and mood
did not differ between the treatment groups.
Net benefit: risk
There were no differences between treatment groups in all-cause mortality (aHR 0.89, 95% CI 0.51 to
1.55; p = 0.69), number and severity of adverse events (acOR 1.02, 95% CI 0.86 to 1.22; p = 0.80),
combined stroke and major/fatal bleeding (aHR 1.24, 95% CI 0.90 to 1.70; p = 0.19) or the composite
of death, stroke, MI and major bleeding (aHR 1.02, 95% CI 0.77 to 1.35; p = 0.88).
Meta-analysis of antiplatelet intensity trials
In a meta-analysis, heterogeneity was present between the group of trials of dual antiplatelet therapy and
the TARDIS trial when compared with guideline therapy in respect of preventing stroke. No heterogeneity
was present for major bleeding.Conclusions
Implications for health carel
l
l
l
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Park,The TARDIS trial found that there was no significant reduction in the recurrence of stroke or TIA, or
their severity, with intensive antiplatelet therapy based on three agents as compared with guideline
therapy. However, triple antiplatelet therapy was associated with increased major bleeding. Overall,
there was no effect on the net balance between harm and benefit confirming the overall neutral
finding of the trial.
In the context of the patients studied in the TARDIS trial, there is no evidence to support the use of
intensive treatment based on three standard antiplatelets (aspirin, clopidogrel, dipyridamole).Future research implicationsThere is no obvious reason to further study the use of intensive antiplatelet therapy with three agents
in patients with acute stroke or TIA.
Future trials examining potent antiplatelet agents should consider whether it would be safe to use
them with existing antiplatelets in patients with acute cerebral ischaemia.Trial registration
This trial is registered as ISRCTN47823388.Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research. The TARDIS vanguard phase was funded by the British Heart Foundation
(grant PG/08/083/25779, 1 April 2009 to 30 September 2012) and indirect funding was provided by the
Stroke Association through its funding of the Stroke Trials Unit, Division of Clinical Neuroscience, University
of Nottingham, Nottingham, UK. There was no commercial support for the trial and antiplatelet drugs
were sourced locally at each site. The trial was sponsored by the University of Nottingham.een’s Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
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Stroke is devastating to patients, carers and society through high mortality (1 in 4 patients by the first year),
morbidity (dependency in 1 in 3 patients by the first year, many of whom need long-term care) and cost
(NHS and social care costs of £1.7B a year in England).1 Both stroke incidence and prevalence will increase as
the UK population ages. Following stroke or transient ischaemic attack (TIA), the risk of recurrence is high,
especially immediately after the event (approximately 10% over the first few weeks), after which it falls to a
total of about 40% by 5 years. Typically, recurrent strokes are more severe than earlier events.2,3
A TIA (‘mini stroke’) is defined as ‘an acute loss of focal cerebral or ocular function with symptoms lasting
less than 24 hours and which is thought to be due to inadequate cerebral or ocular blood supply as a
result of low blood flow, thrombosis or embolism associated with diseases of the blood vessels, heart, or
blood’.4 TIAs are important because they are a key risk factor for subsequent stroke. Patients presenting
with specific TIA features are at a particularly high risk of a subsequent stroke, as assessed by the ABCD2
score5 (as derived from the ABCD score6), which takes account of age (A), blood pressure (B), clinical
symptomology (C), duration of symptoms (D), and presence of diabetes (D). An important caveat is that
data for the training databases used to derive and validate the ABCD2 score were collected up to 1998
and 2005, respectively, and so the absolute risk rates of stroke are now lower as enhanced secondary
prophylaxis has become standard practice. Although some research groups have validated the ABCD2
scoring system,7,8 its value in diagnosis and prognosis after TIA has more recently been questioned.9
The risk of recurrence can be reduced, but not abolished, with lifestyle changes; drug interventions
comprising antithrombotics, antihypertensives and statins; and carotid endarterectomy (after large artery
stroke/TIA).10–12 Although oral anticoagulants are established for cardioembolic stroke,13,14 other patients
with non-cardioembolic ischaemia (the majority) need antiplatelet therapy.15,16 These interventions are
all cost-effective.
The archetypal antiplatelet, aspirin (which is an inhibitor of cyclo-oxygenase), reduces recurrence [i.e. relative
risk reduction (RRR)] by 17% in patients with prior stroke or TIA.17 Clopidogrel (which is an adenosine
diphosphate receptor antagonist) was slightly more efficacious than aspirin in the Clopidogrel vs. Aspirin in
Patients at Risk of Ischaemic Events (CAPRIE) trial.18 Importantly, the relative difference in efficacy between
aspirin and clopidogrel was highest in patients with prior stroke or myocardial infarction (MI).19 No trials
comparing clopidogrel with control or aspirin have been reported in patients with TIA. Dipyridamole
(which inhibits the phosphodiesterase inhibitor-5 and red blood cell uptake of adenosine) reduced
recurrence by 16% in comparison with placebo, and was comparable to aspirin, in the European Stroke
Prevention Study-2 (ESPS-2) trial.20 Evidence now suggests that stroke prevention is dependent on the
number of antiplatelets [e.g. combined aspirin and dipyridamole reduce events by 23% in comparison
to aspirin (or dipyridamole) alone without increasing the risk of bleeding, as seen in the ESPS-2 and
European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) trials].20,21 As with clopidogrel
alone, the difference in efficacy between aspirin and dipyridamole versus aspirin alone was greatest in
patients with the highest baseline risk.22 Similarly, aspirin and clopidogrel was superior to aspirin in cardiac
patients.23,24 However, the superiority of clopidogrel-based dual therapy was not seen in the Clopidogrel
for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA)
trial,25 probably because the apparent benefit in those with prior stroke or MI (who had the highest risk of
recurrence) was diluted by lack of efficacy in those with no previous vascular events (who were at lower
risk). The risk of bleeding with aspirin and clopidogrel versus aspirin was 30–40% higher in these three
trials. The Management of ATherothrombosis with Clopidogrel in High-risk patients (MATCH) trial (aspirin
and clopidogrel vs. clopidogrel) found that dual aspirin and clopidogrel also increased bleeding.26,27© Queen’s Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
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2On the basis of these trials and taking account of the prices of branded clopidogrel and dipyridamole-ER
[£37 and £10 per month, respectively, British National Formulary (BNF)],28 the National Institute for Health
and Care Excellence (NICE) recommended in 2005 that patients should take combined aspirin and
dipyridamole after ischaemic stroke or TIA [Technology Appraisal (TA) number 90].29 In late 2010, NICE
updated its recommendation to aspirin and dipyridamole for TIA, and clopidogrel for ischaemic stroke
(TA210);30 these decisions take account of the large drop in the price of clopidogrel, reflecting its generic
status (£3.40, BNF 6128) but the lack of significant randomised data and a licence for clopidogrel in
patients with TIA. Former and current guidelines have not recommended dual aspirin and clopidogrel
because of increased bleeding.31,32 The preference for combined aspirin and dipyridamole, or clopidogrel
alone, over aspirin alone was also recommended by the European Stroke Organisation in its 2008
guidelines.33 In contrast, the 2011 American Stroke Association secondary prevention guidelines still gave
equal recommendations for aspirin (50–325 mg daily) alone, dual aspirin and dipyridamole, and
clopidogrel (75 mg daily) alone,34 thereby ignoring the results of recent trials.18,20,21,35
The above data for stroke reflect long-term prophylaxis, a very different situation from the situation
immediately after an event when the risk of recurrence is much higher. Conventional acute antiplatelet
therapy is based on aspirin alone for ischaemic stroke reflecting the results of the International Stroke
Trial and Chinese Aspirin Stroke Trial (CAST) megatrials.36,37 However, the effect size is small (absolute risk
reduction ≈1.1%) and, until recently, the acute treatment of TIA had not been investigated. As the risk
of recurrence falls quickly after stroke or TIA, intensive antiplatelet specific treatment is likely to be needed
only for a short period so that the exposure time to hazard (mainly bleeding) is limited. Although
clopidogrel-based dual therapy has not proved effective/safe in long-term stroke prophylaxis, early and
short-term dual antiplatelet therapy based on clopidogrel or dipyridamole may be useful, at least after TIA/
minor stroke, as suggested by several trials [Fast Assessment of Stroke and TIA to prevent Early Recurrence
(FASTER),38 EARLY,39 Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) early]40 and
observational studies [Early use of EXisting Preventive Strategies for Stroke (EXPRESS),41 SOS-TIA42]. In the
FASTER trial (n = 392), 90 days of aspirin and clopidogrel (vs. aspirin) showed a trend to reduce stroke by
absolute 3.7% (not significant), and increased symptomatic intracranial haemorrhage (sICH) by absolute
1% (not significant) leading to a net absolute benefit of 2.7%.38 Similarly, the EARLY trial (n = 543, acute
ischaemic stroke/TIA) found a tendency to reduced vascular events at day 90 with aspirin and dipyridamole
(vs. aspirin, not significant) but no effect on functional outcome.39 A pattern of observations also seen
with aspirin and dipyridamole (vs. clopidogrel) in the PRoFESS early subgroup (n = 1360, mild acute
ischaemic stroke).40
In a meta-analysis of all trials comparing dual with mono antiplatelet therapy in patients with acute stroke
or TIA [including ESPS-2, ESPRIT, CHARISMA, MATCH, PRoFESS early, EARLY, FASTER, Clopidogrel and
Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) and Clopidogrel plus Aspirin for
Infarct Reduction in acute stroke/TIA patients with large artery stenosis and microembolic signal (CLAIR)20,21,
25,26,38–40,43,44], acute dual therapy versus monotherapy within 3 days of ictus significantly reduced stroke
recurrence and a composite of vascular events.45 No significant differences were seen for MI, sICH, major
bleeding or death (but there were few events, Table 146). No heterogeneity existed in any analysis, which
suggested that the composition of dual and monotherapy was not of primary importance. None of the
trials was large enough (each < 1400 patients) to show individual significant differences in stroke or
vascular events. Importantly, the magnitude of effect appeared to decline with time from ictus so trials
recruiting earlier had greater reductions in their point estimates (albeit non-significant because of small
sample size) than those recruiting later: range of odds ratios (ORs) for stroke – early, OR 0.51 to 0.71
(EARLY,39 FASTER,38 PRoFESS early40); later, OR 0.83 to 2.44 (CHARISMA,25 MATCH26). The large
Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial47
compared combined aspirin and clopidogrel with aspirin alone in 5170 Chinese patients with acute minor
stroke or TIA recruited within 24 hours of the event. The results are similar to the meta-analysis and
showed that dual therapy was superior with reduced stroke recurrence [hazard ratio (HR) 0.68, 95%
confidence interval (CI) 0.57 to 0.81] and no difference in moderate or severe haemorrhage.47 The above
meta-analysis45 was updated with CHANCE47 and summarises all available data for acute stroke and TIANIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 1 Main results from meta-analysis of trials of dual vs. mono antiplatelets in patients with acute ischaemic
stroke/TIA; data are taken from published forest plots
Outcome
Number of
data sets
Number of
events
Number of
patients
Risk ratio
(95% CI) p-value
Heterogeneity
I2 (%)
Stroke recurrence 14 668 8796 0.69 (0.60 to 0.80) < 0.001 0
Stroke, TIA, ACS,
all death
9 826 8174 0.71 (0.63 to 0.81) < 0.001 0
Major bleeding 11 37 8466 1.35 (0.70 to 2.59) 0.37 0
ACS, acute coronary syndrome.
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in Table 1. The large POINT trial,48 which also compared combined aspirin and clopidogrel for acute minor
stroke and TIA (within 12 hours) in a Western population, reported similar findings to CHANCE.
Current stroke prevention is far from perfect. Stroke is heterogeneous in type (ischaemic vs. haemorrhage;
lacunar vs. cardioembolic vs. large artery), severity and outcome, and treatments reduce, but do not
abolish, events (‘treatment failure’). In addition, patients may be (relatively) insensitive to treatment
(‘treatment resistance’, as identified for aspirin and clopidogrel49); hence, improvements in secondary
prevention are still needed.
If combined aspirin and dipyridamole is superior to aspirin for long-term secondary prevention,20,21,50
and aspirin and clopidogrel are probably superior to aspirin in acute minor stroke/TIA,38,41,46,47 then triple
antiplatelet therapy (combined aspirin, clopidogrel and dipyridamole) might be better still, providing that the
risk of recurrence is high and bleeding does not become excessive. In this respect, the risk of bleeding when
adding clopidogrel to aspirin and dipyridamole is likely to be similar to that of when adding clopidogrel
to aspirin alone, as dual aspirin and dipyridamole does not increase bleeding over aspirin.20,21 We have
performed a series of ‘proof-of-concept’ laboratory and clinical studies investigating this approach.51–55
Studies in vitro found that triple therapy was most effective in inhibiting aggregation, platelet–leucocyte
conjugation and leucocyte activation.51,54,55 In multiway crossover Phase I and II trials comparing short-term
administration of mono, dual and triple antiplatelet platelet therapies, the combination of aspirin and
clopidogrel, with or without dipyridamole, was most potent in inhibiting platelet function ex vivo in both
normal volunteers (n = 11) and patients with previous stroke/TIA (n = 11).52,53
In the only parallel group trial of triple therapy in patients with stroke (Phase II trial, n = 17), was triple
therapy feasible to administer for up to 24 months.56 The comparator was aspirin, chosen as this
was the UK standard of care at trial commencement. The trial was stopped early on publication of the
ESPRIT trial,21 confirming the superiority of dual aspirin and dipyridamole over aspirin (i.e. it was unethical
to continue patients on aspirin alone). Predictably, there was increased bleeding with long-term triple
therapy versus aspirin. Although unintended, the participants were at a low risk of recurrence (young
age/recruited months after the event/many lacunar strokes), a problem that was also seen in the MATCH
and CHARISMA trials.26,57 A conclusion was that future trials of triple antiplatelet therapy would need to
target patients at a high risk of recurrence so that benefit was likely to outweigh hazard. We have also
used chronic triple antiplatelet therapy in clinical practice in patients at a very high risk of recurrence,
defined as recurrence on dual antiplatelet therapy, and this appeared to be safe.58
Short-term randomised controlled trials of triple antiplatelet therapy have been reported in patients
with acute coronary syndromes (ACSs) or to cover stent insertion (25 studies,59 17,383 patients). In our
published meta-analysis, and in comparison with dual antiplatelet therapy, glycoprotein IIb/IIIa-based triple
therapy reduced MI in patients with non-ST elevation myocardial infarction (NSTEMI) (OR 0.70, 95% CI
0.56 to 0.88) and ST-elevation myocardial infarction (STEMI) (OR 0.26, 95% CI 0.17 to 0.38) patients, and© Queen’s Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3
INTRODUCTION
4vascular events in NSTEMI (OR 0.69, 95% CI 0.55 to 0.86) and STEMI (OR 0.39, 95% CI 0.30 to 0.51)
patients.59 Death was also reduced after STEMI; major bleeding and transfusions were non-significantly
increased and were few in number such that benefit outweighed hazard in absolute numbers of patients.
The number of stroke events were too few to assess any statistical trends, and minimal or no data were
available for other antiplatelets (cilostazol, clopidogrel, dipyridamole).59Rationale for trial
The Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial was predicated on
the following.l
l
l
l
l
l
NIHRThere is a high early risk of recurrent cerebral ischaemic events after stroke and TIA.
Some patients ‘fail’ on monotherapy with aspirin, clopidogrel or dipyridamole.
Dual therapy with aspirin and dipyridamole is superior to aspirin alone after stroke.
Clopidogrel, or dual aspirin and dipyridamole, is the standard of care in the UK (NICE).
If dual therapy is superior, then triple therapy may be better still.
Laboratory studies, Phase I/II trials, and routine clinical use support the use of intensive antiplatelet
therapy with three agents.51–55Hence, triple therapy may be better still in high-risk patients providing the benefits exceed the risk
of bleeding.Journals Library www.journalslibrary.nihr.ac.uk
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The primary objective was to assess ordinal stroke severity at 90 days after short-term administration
(1 month) of triple antiplatelet therapy (aspirin/clopidogrel/dipyridamole) versus standard dual therapy
(aspirin/dipyridamole) in patients with very recent ischaemic stroke or TIA.
Secondary objectives
The secondary objectives were to:
1. assess the safety of short-term administration (1 month) of triple antiplatelet therapy (aspirin/clopidogrel/
dipyridamole) versus standard dual therapy (aspirin/dipyridamole) in patients with very recent ischaemic
stroke or TIA
2. further assess, in high-risk patients with stroke/TIA, whether or not the addition of clopidogrel to
aspirin/dipyridamole (1) is feasible to administer acutely and tolerable to take for 1 month, (2) is
superior in respect of surrogate markers such as emboli [with transcranial Doppler (TCD)] and platelet
function and (3) improves functional outcome
3. assess whether or not ordinal outcomes are superior to binary events.Design
The TARDIS trial was an international Prospective Randomised Open-label Blinded End point (PROBE) study
that recruited from 106 sites in four countries (Denmark, Georgia, New Zealand and the UK). The protocol
can be found online.60Study settings
The trial was carried out in the stroke services of 106 hospitals in four countries: the UK, Denmark,
Georgia and New Zealand. Stroke services were housed in a range of settings including teaching/tertiary
and district/secondary hospitals (see list in Appendix 1).Participants
Adult patients aged ≥ 50 years were eligible for inclusion if they were at risk of a recurrent ischaemic
stroke, and had either a non-cardioembolic ischaemic stroke or a non-cardioembolic TIA. Randomisation
had to be performed within 48 hours of symptom onset unless the participants had received intravenous
thrombolysis, in which case randomisation had to be performed once 24 hours had elapsed after the end
of this treatment and post-treatment neuroimaging excluded secondary cerebral bleeding. Patients gave
written consent, or written proxy consent was obtained from a relative or carer if the patient lacked
capacity. The consent form and patient information sheet are available at www.journalslibrary.nihr.ac.uk/
programmes/hta/1010424/#/ (accessed July 2018). The full criteria follow here.
Inclusion criteria
Adults at a high risk of recurrent ischaemic stroke who:
1. were aged ≥ 50 years
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6had TIA with limb weakness and/or dysphasia lasting between 10 minutes and < 24 hours with no
residual symptoms and presenting with any of the following:i.
ii.
iii.
iv.
i.
ii.
iii.
iv.
v.
vi.
vii.
viii.
.
.
.
.
.
.
.
.
R Jouran ABCD2 score of ≥ 4
crescendo TIA
already be on dual antiplatelet therapy with aspirin and dipyridamole
positive neuroimaging evidence to support the new event, ischaemic stroke on magnetic resonance
diffusion imaging.
– Patients who were on monotherapy (e.g. aspirin alone, clopidogrel alone or dipyridamole alone)
were eligible for recruitment. Similarly, patients who were on combined therapy aspirin and
dipyridamole were eligible for recruitment if they fulfilled the above criteria.
– Patients with posterior fossa events were eligible if they fulfilled the above criteria.
– Neuroimaging was not necessary for TIA. Crescendo TIA was defined as more than one TIA in the
immediate previous week, and the time of onset of the last TIA was taken as the time of ictus.Ischaemic non cardioembolic stroke presenting with any of the following:nongoing limb weakness of more than one hour duration and/or
ongoing dysphasia of > 1 hour duration and/or
resolved limb weakness of > 1 hour duration with ongoing facial weakness and/or
ongoing isolated hemianopia of > 1 hour duration with positive neuroimaging evidence to support
the new event (e.g. ischaemic stroke in the occipital lobe) and/or
limb weakness that resolves between 24–48 hours after onset and/or
dysphasia that resolves between 24–48 hours after onset and/or
positive neuroimaging to support the new ischaemic event with magnetic resonance diffusion
and/or
already on dual antiplatelet therapy with aspirin and dipyridamole:
– Neuroimaging was essential for ischaemic stroke to exclude intracranial haemorrhage and
non-stroke diagnoses. If the patient received thrombolysis, a post-thrombolysis/pre-TARDIS
brain CT scan had to be done to exclude new thrombolysis associated bleeding prior to
enrolment. Typically, this was done as ‘standard of care’, but if it was not done routinely
then it had to be done prior to enrolment.5. Patients thrombolysed for stroke with full recovery in < 24 hours from the onset of symptoms were
eligible for inclusion providing neuroimaging post-thrombolysis excluded intracranial haemorrhage.
6. Informed consent from participant. If the participant was unable to give meaningful consent (e.g. owing
to dysphasia, confusion or reduced conscious level, proxy consent could be obtained from a relative,
carer, friend or legal representative).
Exclusion criteriaAged < 50 years.
Isolated sensory symptoms or vertigo/dizziness or facial weakness.
Isolated hemianopia without positive neuroimaging evidence.
Intracranial haemorrhage.
Baseline neuroimaging showing a parenchymal haemorrhage (PH) transformation (I/II) of infarct,
subarachnoid haemorrhage or other non-ischaemic cause for symptoms.
Presumed cardioembolic stroke [e.g. a history of or current atrial fibrillation (AF), MI within 3 months].
Participants with contraindications to, or intolerance of, aspirin, clopidogrel or dipyridamole.
Participants with definite need for treatment with aspirin, clopidogrel or dipyridamole individually or in
combination (e.g. aspirin and clopidogrel for recent MI/ACS).als Library www.journalslibrary.nihr.ac.uk
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Park, SDefinite need for full dose orally [e.g. warfarin, dabigatran (Pradaxa®, Boehringer Ingelheim, Bracknell, UK)]
or medium- to high-dose parenteral (e.g. heparin) anticoagulation. Note that low-dose heparin for deep-vein
thrombosis (DVT) prophylaxis was allowed.
Definite need for glycoprotein IIb–IIIa inhibitors.
Patients who had received thrombolysis within 24 hours.
No enteral access.
Pre-morbid dependency [modified Rankin Scale (mRS) score of > 2].
Severe high blood pressure (> 185/110 mmHg).
Haemoglobin levels of < 10 g/dl.
Platelet count > 600 × 109/l or < 100 × 109/l.
White cell count of > 30 × 109/l or < 3.5 × 109/l.
Major bleeding within 1 year (e.g. peptic ulcer, intracerebral haemorrhage).
Planned surgery during 3-month follow-up (e.g. carotid endarterectomy).
Concomitant STEMI or NSTEMI.
Stroke secondary to a procedure (e.g. carotid or coronary intervention).
Coma [Glasgow Coma Scale (GCS) score of < 8).
Non-stroke life expectancy < 6 months.
Dementia.
Participation in another drug or devices trial concurrently or within 30 days (participants may take part
in observational studies or non-drug or devices trials).
Geographical or other factors that may interfere with follow-up (e.g. no fixed address or telephone
contact number, not registered with a general practitioner, or overseas visitor).
Females of childbearing potential, pregnancy or breastfeeding.
Patients who have not had post-thrombolysis neuroimaging.
Patients on aspirin and clopidogrel prior to the underlying event.Data collected at baseline
Baseline data collected immediately prior to randomisation included demographic information (age, sex
and ethnicity), medical history including vascular risk factors, current antiplatelet therapy (none, aspirin,
clopidogrel, dipyridamole, other), and pre-morbid dependency (mRS, scores range from 0 to 6, with a
score of 0 indicating no symptoms, 5 indicating severe dependency and 6 indicating death61,62). Clinical
information included blood pressure and stroke syndrome [Oxfordshire Community Stroke Project (OCSP)63].
Neurological impairment was recorded in stroke patients using the National Institutes of Health Stroke Scale
(NIHSS), for which scores range from 0 to 42 with higher scores indicating a more severe neurological
deficit.64,65 The risk of recurrence after index TIA was assessed using the ABCD2 scale (scores range from
0 to 7 with higher scores indicating a higher risk of recurrence5).Interventions
Participants randomised to the intervention (intensive, triple antiplatelets) group received combined aspirin
(load 300 mg, maintenance 50–150 mg daily, typically 75 mg, given orally, nasogastrically or rectally),
clopidogrel (load 300 mg, maintenance 75 mg daily, given orally or nasogastrically) and dipyridamole
(200 mg twice daily modified release, given orally; or 100 mg three or four times daily, given orally or
nasogastrically). Those randomised to guideline antiplatelet therapy received either combined aspirin and
dipyridamole or clopidogrel alone, using the loading and maintenance doses given above.
The two approaches for guideline therapy arose because of a change in clinical guidelines. At the start of
the trial, NICE recommended the use of aspirin and dipyridamole for secondary prevention29 and the initial
trial protocol defined this as the guideline comparator. Once clopidogrel became generic (and its price fell),
NICE updated their guidance in 2010 with a recommendation that clopidogrel should be used first line foren’s Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
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outhampton SO16 7NS, UK.
7
METHODS
8secondary prophylaxis after ischaemic stroke (but not TIA because clopidogrel was not licensed for TIA and
there was an absence of randomised trial data for this indication)30 and the protocol was updated accordingly.
Randomised antiplatelet drugs were given for 30 days so as to influence the time period of high risk
of recurrence without intending to accrue significant bleed. After 30 days, participants were treated in
accordance with local/national guidelines, typically with combined aspirin and dipyridamole or clopidogrel
alone. Drugs were sourced by each participating hospital with supply from any licensed manufacturer
(including generic sources).
Detailed information on compliance with randomised treatment was collected up to 7 days, but not during
the subsequent 21 days to end of treatment.
At the start of the trial, clopidogrel was available as a branded drug, Plavix® (Sanofi Guildford, UK).
Subsequently, multiple generic versions became available with the advantage of a much lower cost; as a
result, recruiting sites increasingly used generic clopidogrel. A number of studies and a meta-analysis have
compared Plavix with generic clopidogrel and these do not report any significant difference in antiplatelet
responses or effects on vascular outcomes.66–69Randomisation
Demographic and baseline clinical characteristics were entered online into a secure web-based database
system,70 which was a bespoke system that also provided randomisation and was based on that used in
the Efficacy of Nitric Oxide in Stroke (ENOS) trial and the Prevention of Decline in Cognition After Stroke
Trial (PODCAST).71,72 Baseline data were checked to confirm the patient’s eligibility and the system then
assigned the participant to intensive or guideline antiplatelet therapy, with a 1 : 1 allocation.
Patients randomised to the guideline group received either combined aspirin and dipyridamole, or
clopidogrel alone, in accordance with local policy and guidelines, and antiplatelets taken prior
to randomisation.l
l
NIHREach site chose what comparator(s) they wished to use for ischaemic stroke and TIA separately.
They could elect to use one comparator only, or randomise between the comparators. The principal
investigator could change the choice of comparison group(s) via the database at any stage during the
trial, but changes took 48 hours to take effect to avoid them being made for individual participants.
The elected comparator option of each site (irrespective of whether a participant was eventually
randomised to intensive or guideline treatment) has been included as a covariate in all adjusted
analyses and investigated as part of the prespecified subgroup analysis.
As aspirin and clopidogrel have irreversible effects on platelets while platelets circulate for 7–10 days,
randomisation also took account of which antiplatelet(s) had been taken shortly before stroke onset or
in hospital prior to randomisation. The concern was that the comparator group might amount to triple
antiplatelet therapy once pre-randomisation treatment was taken into account. However, because
aspirin is widely taken both before stroke and immediately following scanning in hospital, it was
allowed in all choices prior to randomisation. For example, a patient on clopidogrel prior to stroke and
given aspirin in hospital could not be randomised to aspirin and dipyridamole as this would functionally
result in them being exposed to all three drugs for the first week after randomisation. As a result,
the following rules were followed at the time of randomisation when determining an appropriate
comparator (Table 2).Randomisation comprised stratification on country and index event (stroke vs. TIA), and minimisation on key
prognostic baseline factors [age, sex, pre-morbid function (using the mRS), systolic blood pressure, syndrome
(cortical vs. lacunar63), previous antiplatelet therapy (none/mono vs. dual), use of gastroprotection, use of low
dose heparin and time to randomisation]. For TIA participants, minimisation also included presence ofJournals Library www.journalslibrary.nihr.ac.uk
TABLE 2 Rules for determining a suitable comparator depending on prior antiplatelet exposure
Pre stroke Post stroke Allowed comparator(s)
Nil Nil Clopidogrel vs. aspirin and dipyridamole
Nil Aspirin Clopidogrel vs. aspirin and dipyridamole
Aspirin Aspirin Clopidogrel vs. aspirin and dipyridamole
Clopidogrel Nil Clopidogrel alone
Clopidogrel Aspirin Clopidogrel alone
Dipyridamole Nil Aspirin and dipyridamole
Dipyridamole Aspirin Aspirin and dipyridamole
DOI: 10.3310/hta22480 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 48crescendo TIAs (more than one TIA in the previous week) and ABCD2 score;5 for those with stroke,
minimisation also included NIHSS and treatment with alteplase.Definition of events (updated from the statistical analysis plan)73
Stroke, MI and bleeding (major, moderate) are adjudicated independently by two adjudicators; if they
differ in type of vascular event or severity of bleeding, a third adjudicator also assesses the event and a
majority view is recorded for analysis. Serious adverse events (SAEs) are assessed by a single adjudicator.
All adjudicators are blinded to treatment assignment.
Adherence
Details on tablets taken were only recorded over the first 7 days after randomisation. Hence, adherence
was judged as whether or not the first treatment was received, and whether or not all of the first week’s
treatment was taken. Reasons for non-adherence during the first 7 days were recorded.
Asymptomatic intracerebral haemorrhage
Any haemorrhage seen on computed tomography (CT)/magnetic resonance imaging (MRI) scanning,
if done after randomisation, with no neurological deterioration (as defined here).
Bleeding
Major bleed74l
l
l
l
l
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Park,Fatal bleeding and/or
symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular,
retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or
bleeding causing fall in haemoglobin of ≥ 20 g/l (≥ 1.24 mmol/l), or leading to transfusion of ≥ 2 units
of whole blood or red blood cells.Moderate bleedNot major bleed and
bleeding causing fall in haemoglobin of ≥ 10 g/l (≥ 0.62 mmol/l) but < 20 g/l (< 1.24 mmol/l) and
leading to no transfusion, or transfusion of only 1 unit of whole blood or red blood cells.een’s Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
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10Minor bleedl
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NIHRNot major or moderate bleed and
comprising bruising, ecchymoses, gingival bleed or similar other type of bleeding. Note: this excludes
asymptomatic intracranial haemorrhage.Deep-vein thrombosis, symptomatic
Clinical suspicion of DVT will need confirmation by either venography or ultrasound examination.
Disposition
Disposition is categorised as death, institution or home:Institution refers to warden controlled, residential home, care home, nursing home, still an inpatient,
or readmitted to hospital.
Home refers to home alone, home with spouse/carer or at carer’s home.Extracranial haemorrhage, major
An extracranial bleed that is major in severity (see Major bleed).
Feeding status
Feeding status is defined as:oral – normal diet, soft diet
non-oral – nasogastric tube fed, percutaneous endoscopic gastrostomy (PEG)-tube fed, intravenous/
subcutaneous fluids, no feeding/fluids.Headache, requiring treatment or cessation of treatment
A headache occurring during treatment that necessitates intervention, including withdrawing
antiplatelet treatment.
Intracerebral haemorrhage, secondary on computed tomography/magnetic resonance
imaging scanning
Haemorrhagic infarct (HI): petechial infarction without space occupying effect –HI1: small petechiae
HI2: more confluent petechiae.Parenchymal haemorrhage: haemorrhage with mass effect –PH1: < 30% of the infarcted area with mild space occupying effect
PH2: > 30% of the infarcted area with significant space occupying effect.Note: patients with PH should not be enrolled into the trial.
Intracerebral haemorrhage, symptomatic
Neurological deterioration or death, associated with intracerebral haemorrhage found on CT/MRI scan or
autopsy. The haemorrhage must be the predominant cause of the neurological deterioration.
Note: this excludes other forms of intracranial haemorrhage, including extradural, subdural and
subarachnoid haemorrhage, which will be reported separately.
Intracranial haemorrhage
Symptomatic intracranial haemorrhage, extradural haemorrhage, subdural haemorrhage and/or
subarachnoid haemorrhage.Journals Library www.journalslibrary.nihr.ac.uk
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Either one of the following criteria satisfies the diagnosis for an acute, evolving or recent MI:75l
l
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Southischaemic symptoms
development of pathologic Q waves on the electrocardiography (ECG)
ECG changes indicative of ischaemia (ST segment elevation or depression) or
coronary artery intervention (e.g. coronary angioplasty).C
ePathological findings of an acute MI –STEMI: MI with ST elevation on ECG
NSTEMI: MI with no ST elevation on ECG.Neurological deterioration
An increase in NIHSS by ≥ 4 points over the baseline value.
Pulmonary embolism, symptomatic
The clinical suspicion of pulmonary embolism will need confirmation by either high-probability ventilation-
perfusion lung scintigraphy, pulmonary angiography, inconclusive V/Q scan and DVT, or lead to death.
Recurrent stroke, symptomatic
A stroke, defined as below, occurring after the qualifying stroke, or a progression of neurological
symptoms or signs (increase in NIHSS score of ≥ 4) in the same vascular territory as the index event.
Classified as haemorrhagic or ischaemic (if documented by CT/MRI scan or autopsy), or of unknown type.
The time from stroke onset and lesion side will be noted.
Note: this definition deliberately does not attempt to differentiate true recurrence from extension of the
presenting lesion as this is clinically and radiologically difficult unless recurrence occurs in a new arterial territory.
Stroke
A clinical syndrome characterised by rapidly developing clinical symptoms and/or signs of focal (and at
times global) loss of cerebral function with symptoms lasting ≥ 24 hours or leading to death, with no
apparent cause other than that of vascular origin.
Transient ischaemic attack
A sudden focal neurological deficit of the brain or eye, presumed to be of vascular origin and lasting
< 24 hours.
Note: the tissue diagnosis of TIA based on the results of MRI scanning will not be used as MRI scanning is
not routinely available out of hours at many participating hospitals.
Time at home
Calculated as time from date of discharge to day 90 or death if earlier; those who die in hospital or are
discharged to a non-home setting are given a score of zero. Readmission to hospital is not counted in this time.
Unstable angina
Presence of acute cardiac chest pain at rest without ST elevation on ECG and without elevation in
cardiac enzymes.Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
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12Venous thromboembolism, symptomatic
Symptomatic DVT and/or symptomatic pulmonary embolism.Assessments after randomisation
Participants were seen in clinic at days 7 (on treatment) and 35 (end of treatment plus 5–7 days to allow for
wash-out) to ascertain whether any outcome or bleeding events had taken place (this included performing a
full blood count) and to determine compliance with treatment. Final follow-up was performed centrally at
90 days by telephone from the co-ordinating centre in each country, with the assessor blinded to treatment
allocation. If the participant could not be contacted (following multiple attempts), a questionnaire covering
the same outcome measures was sent by post. Identification of recurrent cerebrovascular events used multiple
sources of information: assessment by the investigator at days 7 and 35, or via serious adverse event (SAE)
reporting, patient reporting at day 90 telephone follow-up, and by the general practitioner following a
questionnaire posted to them shortly after day 90. The primary outcome, bleeding and investigator-reported
SAEs (including cause-specific case fatality) were validated and categorised by expert adjudicators who were
blinded to treatment assignment. Participants who did not receive their assigned treatment or who did not
adhere to the protocol were still followed up in full at day 90.Primary efficacy outcome
The primary efficacy outcome was the incidence and severity of recurrent stroke and TIA occurring by
90 days. The timing of 90 days was chosen to emulate the usual follow-up period in acute stroke trials.
Severity of recurrent stroke was assessment of the mRS, a six-level ordered categorical scale:76,77 fatal
stroke, non-fatal severe stroke (mRS score of 4–5), moderate stroke (mRS score of 2–3), mild stroke
(mRS score of 0–1), TIA and no stroke or TIA.77 The primary outcome was a balance of ischaemic stroke
(potential benefit if reduced) and intracerebral haemorrhage (potential harm if increased).
Originally, the intention was to analyse across nine levels of severity comprising the individual seven
levels of mRS, TIA and no event (protocol version 1.1, dated 17 October 2008; protocol version 1.2,
dated 20 May 2009). Subsequently, the scale was reduced to five levels: fatal stroke, moderate to severe
stroke (mRS score of 2–5), mild stroke (mRS score of 0–1), TIA and no event (protocol version 1.3,
dated 20 December 2011; protocol version 1.4, dated 26 February 2013; protocol version 1.5, dated
28 February 2014). Finally, the scale was increased to six levels.73 The changes resulted from multiple
discussions among the statistical and clinical teams on simplifying the scale (from nine levels) but not
overmerging mRS levels, in particular, keeping mild, moderate and severe stroke separate. These changes
occurred during enrolment when the database was locked. A post hoc analysis comparing these three
approaches (5, 6, 9 levels) was performed.
Choice of the primary efficacy outcome
Clinical trials are increasingly having to increase their sample size, largely because major advances have
been made in preventing cardiovascular events (including stroke and TIA), which has meant that the risk
of recurrent events has fallen. Furthermore, the number of randomised trials has also increased. As a result,
it is increasingly difficult to find sufficient participants to enter trials. Vascular prevention studies typically
count outcomes as dichotomous events (e.g. event vs. no event) although this is inefficient statistically and
gives no indication regarding the severity of the recurrent event. Recurrent vascular events, such as stroke,
could therefore be polychotomised with ordering of outcome events determined by severity.
The purpose of using an ordinal outcome was twofold. First, it allowed the effect of treatment to be
assessed on the severity of recurrent events as well as their rate. In general, interventions that reduce the
risk of recurrence (such as antithrombotics, blood pressure- and lipid-lowering therapies, and carotid
surgery) also reduce the severity of those events that do occur;76,78 similarly, interventions that increaseNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22480 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 48recurrence (e.g. hormone replacement therapy) also increase the severity of events.79 Second, ordinalising
dichotomous events improves statistical power so that sample size can be reduced for a given power,
or power increased for a given sample size. Such an approach could reduce trial costs while improving
statistical efficiency and amplifying the potential to demonstrate a treatment effect.
The approach can be used with any dichotomous outcome that can encompass a measure of severity, such
as recurrence of stroke/TIA, bleeding and SAEs (as done here).76 Other outcomes, such as MI, heart failure
and venous thromboembolism, can be analysed in the same way. Although this approach has been tested
empirically using published data,76,78,79 the TARDIS trial is the first trial to use the method prospectively.Secondary efficacy outcomes
Prespecified secondary outcomes at day 9080 included activities of daily living [Barthel Index (BI)81],
cognition [modified telephone Mini-Mental State Examination (t-MMSE),82 Telephone Interview for
Cognition Scale – modified (TICS-M),83 categorical verbal fluency using animal naming84], health-related
quality of life [EuroQol-5 Dimensions, three-level version (EQ-5D-3L),85 from which health status utility
values (HSUVs) were calculated; EuroQoL Visual Analogue Scale (EQ-VAS)], and mood [short Zung
Depression Scale (ZDS)86]. At discharge from initial hospitalisation, duration of hospital stay and discharge
disposition (institution or home) were recorded.Safety outcomes
The main safety outcome was bleeding comprising a five-level ordered categorical scale: fatal, major,
moderate, minor and none.76 The definitions of fatal, major and moderate bleeding were those of the
International Society on Thrombosis and Haemostasis and are based on severity, site, fall in haemoglobin
and need for transfusion.74 Additional safety outcomes included all-cause and cause-specific case fatality,
early neurological deterioration (defined as an increase from baseline to day 7 of at least 4 points on the
NIHSS and/or decrease in the consciousness component of the NIHSS), and SAEs.
Information on recurrent stroke and TIA, MI and bleeding was collected using the SAE reporting forms,
with additional information specific to the outcome.Net balance in efficacy and safety
To assess the net balance between efficacy and hazard, composite end points of any stroke or major
(including fatal) bleeding, and death, stroke, MI or major bleeding, were analysed.Study oversight
The trial was conceived and designed by the grant applicants who wrote the protocol (available at
http://tardistrial.org/jevpybki.htm). The study was approved by national and/or local ethics committees in
each participating country and site, was registered (ISRCTN47823388) and adopted in the UK by the
National Institute for Health Research (NIHR) Stroke Research Network. The trial was overseen by a Trial
Steering Committee (TSC) (which included five independent members and a patient–public representative)
and an International Advisory Committee (comprising each national co-ordinator). The day-to-day conduct
of the trial was run by a Trial Management Committee based at the TARDIS co-ordinating centre in the
Stroke Trials Unit in Nottingham. Study data were collected, monitored and analysed in Nottingham.
Analysis, interpretation and report writing were performed independent of the funders and sponsor,
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14the first draft of this report; this and subsequent drafts were edited by the grant applicants, who all
approved the decision to submit the manuscript for publication. The corresponding author and two
statisticians (LJW, KF) had full access to all the data in the study. In addition, the corresponding author
had final responsibility for the decision to submit for publication and is the guarantor for the study.
Data Monitoring Committee
An independent Data Monitoring Committee (DMC) reviewed unblinded data in confidence every
6 months; altogether they met on 13 occasions and recommended trial continuation for all but the last
data review. The DMC was responsible for safeguarding the interests of trial participants, assessing the
safety and efficacy of the intervention during the trial, assessing data integrity and monitoring the overall
conduct of the trial. The DMC reviewed the recruitment of participants and assessed safety and efficacy
measures by treatment group.
The DMC followed a pre-defined charter and were charged with informing the TSC if, at any time, the
data showed evidence beyond reasonable doubt of a difference between the randomised groups in the
primary outcome. They also considered data in the light of external information such as results from
completed trials. One interim analysis was performed. In addition, the DMC could perform statistical
assessments whenever they deemed it necessary.
The DMC were given specific stopping rules for efficacy and hazard but not futility; stopping criteria were
based on the Haybittle–Peto rule (i.e. a difference of three standard errors was to be considered as clear
evidence of a treatment effect):
The balance between safety and efficacy should be considered.
With respect to safety, the following outcomes in particular will initiate discussion and minuting of detailed
reasons for recommending early stopping or continuation of the study:l
l
l
l
l
NIHRThe primary outcome (‘shift’ in mRS in participants having a recurrent stroke event or TIA) favours the
control group (who receive standard antiplatelet therapy but not clopidogrel); p < 0.01 (nominal,
two-sided).
Combined outcome of fatal or non-fatal stroke or major bleeding favours the control group, p < 0.01
(nominal, two-sided).
The overall rate of sICH exceeds 2%.
During the vanguard phase, major bleeding favours the control group; p < 0.01 (nominal, two-sided).In making any decision, the committee will consider the overall internal and external evidence, the
multiplicity of testing and the possibility that the trends in the data might be reversed with longer
follow-up or increased recruitment.
With respect to efficacy, the committee will conduct formal interim analyses, after 40% and 70% of the
target number of participants have been enrolled and had their 90-day outcome assessed, based on the
following outcome.Combined outcome of fatal or non-fatal stroke or major bleeding event favours the clopidogrel group;
p < 0.001 (two-sided).In making any decision, the committee will consider the overall internal and external evidence.Journals Library www.journalslibrary.nihr.ac.uk
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As outcomes such as mRS, EQ-5D-3L/HSUV and BI include scores for death (6, 0 and –5, respectively)
and in case treatment was associated with asymmetric effects on death and other outcome measures
(e.g. more death and less impairment), an extreme value for death was added to the other outcome scales:
EQ-VAS = –1, t-MMSE = –1, SSS = –1, TICS-M = –1, verbal fluency = –1, and ZDS = 102.5.77,87 Including
death in these secondary outcome scores has the additional advantage of increasing statistical power and
of anchoring the scales to one another.Statistical analyses
Statistical analyses were performed according to the published statistical analysis plan73 by Lisa J Woodhouse
and Katie Flaherty (with oversight by SP) using SAS® software (version 9.3) (SAS Institute Inc., Cary, NC, USA;
SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of
SAS Institute Inc. in the USA and other countries. ® indicates USA registration). Analyses were by intention
to treat for all comparisons (i.e. according to the treatment group participants were allocated to and
irrespective of the treatment they actually received). Data are shown as number (%), median [interquartile
range (IQR)], mean [standard deviation (SD)] and OR (95% CIs).
Analysis of the effect of treatment on the primary efficacy outcome was analysed as a shift in stroke
and its severity [fatal stroke, non-fatal severe stroke (mRS 4–5), moderate stroke (mRS 2–3), mild stroke
(mRS 0–1), TIA and no stroke or TIA] with adjustment for the factors used in stratification and minimisation
at the time of randomisation (index event – ischaemic stroke, TIA; country; guideline randomisation
choice – aspirin/dipyridamole, clopidogrel, either; age; sex – female, male; pre-morbid mRS; time from
onset to randomisation; number of antiplatelets before index event; stroke syndrome – lacunar syndrome
(LACS), posterior circulation syndrome (POCS), partial anterior circulation syndrome (PACS), total anterior
circulation syndrome (TACS) systolic blood pressure; gastroprotection – yes, no; use of heparin – yes, no;
stroke severity – NIHSS; treated with recombinant tissue plasminogen activator – yes, no; ABCD2 score;
number of TIA in last week88) and is reported as an adjusted common odds ratio (acOR) with 95% CIs.
The common odds ratio (cOR) represents the odds of a patient on treatment moving categories of
outcome as compared with a patient on control; cOR < 1 suggests benefit and cOR > 1 hazard. The OR
and significance were calculated using ordinal logistic regression following a check (using the likelihood
ratio test) that the assumption of common proportional odds was not violated. For sensitivity purposes, the
primary outcome was also analysed without adjustment and as a binary outcome of fatal or major stroke.
The heterogeneity of the treatment effect on the primary outcome was assessed in prespecified subgroups
by adding an interaction term in an unadjusted ordinal logistic regression model. Similarly, the effect of
treatment on the main safety outcome was analysed as a shift in bleeding and its severity (fatal, major,
moderate, minor and none) with adjustment for the stratification and minimisation factors. For sensitivity
purposes, bleeding was also analysed unadjusted, as a binary outcome of fatal and major bleeding,
heterogeneity within subgroups was also assessed. The composite outcomes of stroke or major bleeding,
and death, stroke, MI or major bleeding were compared between treatment groups using adjusted
Cox regression.
Death was analysed using Kaplan–Meier and Cox regression models. Other outcomes were analysed using
adjusted multiple linear regression (BI, ZDS, t-MMSE, TICS-M, verbal fluency, EQ-5D/HSUV and EQ-VAS).
All analyses were also performed unadjusted for completeness. The nominal level of significance for all
analyses, including interaction testing, was p < 0.05. No adjustment was made for multiplicity of testing for
secondary analyses.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
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The TARDIS trial was designed with a vanguard phase to assess safety, feasibility and tolerability [funded
by the British Heart Foundation (BHF)] and a main phase to assess safety and efficacy (funded by NIHR
Health Technology Assessment).
The null hypothesis (H0) was that intensive antiplatelets would not alter the frequency and severity of
stroke/TIA in participants with previous ischaemic stroke or TIA. The alternative hypothesis was that the
frequency and severity of stroke/TIA would differ between those participants randomised to intensive
versus guideline antiplatelets. A total sample size89,90 of 4100 (2050 per group) participants with ischaemic
stroke or TIA was required, assuming overall type I error rate (significance, alpha) = 0.05 with two-sided
significance test. Power (1-beta) = 0.90, OR = 0.68 (equivalent to an OR = 0.57 and RRR = 0.31 for binary
stroke), distribution in outcome as in Table 3, treatment crossovers 5% and losses to follow-up 2%, and a
reduction of 20% for baseline covariate adjustment.90,91 No adjustment was made for two interim analyses
in view of the stringent stopping rules given to the DMC (see above).
Originally, a five-level stroke/TIA ordered outcome was planned with distribution based on data from the
TARDIS trial during the vanguard phase (n = 392) (see Table 3). However, this was changed to a six-level
scale to allow discrimination of moderate and severe non-fatal stroke outcomes, and to keep together
mRS scores of 2 and 3 (which can be challenging to separate clinically). Distribution of mRS came from
blinded data from a TSC report (based on n = 1460 participants).Protecting against bias, including blinding
Multiple measures were taken to minimise bias: recruitment on the basis of predefined inclusion/exclusion
criteria, with exclusion of patients enrolled in other trials; central data registration with real-time data
validation and concealment of allocation; blinded central telephone assessment of day 90 outcomes by the
National Coordinating Centre (NCC) staff; assessment of patient recall of treatment;92 blinded adjudication
of outcomes (stroke/TIA, MI, bleeding), SAEs and CT/MRI scans; research staff trained in trial protocol and
processes; analysis by intention to treat; analyses adjusted for baseline prognostic variables, including
minimisation factors; adjustment for non-randomised acute treatment (thrombolysis with alteplase).Neuroimaging scan adjudication
The CT or MRI brain scans were performed in accordance with local site practice at baseline in all
patients with ischaemic stroke to confirm the diagnosis. Investigators decided whether or not to perform
neuroimaging in patients with TIA depending on clinical need. Sites could also perform follow-up scans at
any time point after enrolment according to clinical need (e.g. if a neurovascular outcome or bleeding was
suspected). For this publication, scan-derived information is based on radiological reporting from local sites.TABLE 3 Anticipated distribution of mRS in sample size calculations (adapted from the statistical analysis plan)73
mRS (%) No event TIA 0–1 2–3 2–5 4–5 6 (death)
Initial assumption 93.82 3.57 1.53 0.77 0.51
Final assumption 93.15 3.22 1.23 1.30 0.55 0.55
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submitted to the International Coordinating Centre in Nottingham using one of two methods:
1. Uploaded onto the trial website as uncompressed encrypted non-anonymised digital imaging and
communications in medicine (DICOM) files. Once the trial system had validated the files against the
expected patient details, the files were then anonymised.
2. Sent by courier on a compact disc read-only memory (CD-ROM) or digital versatile disc (DVD), with files
in DICOM format with pseudo-anonymisation of patient details; the patients were identified with their
unique study number and initials.
When reviewed, some images were in non-DICOM format [e.g. portable network graphic (PNG), Joint
Photographic Experts Group (JPG)] and these were converted to DICOM. The anonymised image files
were then presented to a panel of expert adjudicators using a browser-based system driven from the trial
database. Adjudicators were trained and assessed using the ACCESS system [https://sirs2.ccbs.ed.ac.uk/sirs2
(accessed August 2018)]93,94 and reviewed scans blinded to treatment assignment. Adjudication parameters
were derived from the International Stroke Trial-3 and ENOS trial image adjudication systems71,95 and included
information on:l
l
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Park,the presence of an acute stroke lesion – location, mass effect and presence of secondary ischaemia
or haemorrhage
the presence of pre-stroke changes – atrophy, white matter hyperintensities, old stroke.Information from adjudication was used to inform the final diagnosis for all participants with a received
scan. When clinical and radiological information were incongruent, Robert A Direen performed a second
adjudication to confirm imaging findings.Sites, investigators and monitoring
Training of investigators
All TARDIS investigators were trained in good clinical practice (through their host institution), the protocol
and use of three assessment scales: NIHSS, mRS and BI. In addition, national telephone outcome assessors
were trained and then tested with case scenarios in the mRS.
Schedule for monitoring of sites and data integrity
Site monitoring was performed by each NCC with the aim of ensuring quality control of the delivery of the
protocol, collection of data and adherence with national regulations and ethics. Each recruiting site had
a start-up visit for training and at least one monitoring visit; further visits were performed as deemed
necessary by the NCC. Monitoring visits confirmed the presence of the participant and their consent,
eligibility criteria, selected data critical to the trial (demographics, prescription of interventions and blood
pressure) and reported SAEs.
Central statistical monitoring of the data was performed according to Buyse et al.96 during the trial and
prior to the locking of the data. Checks included logic and range checks, digit preference, comparison of
univariate data between sites and comparison of multiple variable models between countries. The monitoring
procedures were compliant with the requirements of the sponsor, the national ethics committees and
regulatory authorities in the participating countries, and fulfilled good clinical practice requirements.Protocol amendments
Five protocol amendments were made during the trial, these started from version 1.1.een’s Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
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18Protocol version 1.1 to 1.2 (20 May 2009)l
l
l
l
l
l
l
l
NIHRInvestigational medicinal product (IMP): only clopidogrel-considered IMP, not aspirin and dipyridamole
which are considered standard/routine treatment.
Secondary end points added: incidence and type of infection.
Inclusion criteria added:¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
JourAll strokes must have motor weakness or dysphasia at time of randomisation.
All TIAs must have motor weakness or dysphasia lasting at least 10 minutes.
The ABCD score of > 4 changed from a score of > 5.nExclusion criteria changed:Aged < 50 years changed from < 40 years.
Motor weakness or dysphasia lasting < 10 minutes changed from < 30 minutes.
Patients with definite need for treatment with clopidogrel (e.g. recent MI).
Definite need for full-dose oral (e.g. warfarin) or parenteral (e.g. heparin or glycoprotein IIb IIIa
inhibitors) anti-coagulation. (Low-dose heparin for DVT prophylaxis is allowed.)
Definite need for, or currently on, triple antiplatelet therapy or anticoagulation.
Received thrombolysis within the last 30 hours changed from indication for, or received (in last
week), thrombolysis.
Pre-morbid dependency mRS score of > 2 changed from a mRS score of > 3.
Known haemoglobin < 10 g/dl.
Known platelet count < 100 × 109/l.
Known white cell count < 3.5 × 109/l.
Planned surgery during the first month post stroke (e.g. carotid endarterectomy) deleted.Statistics: added – the effect of the intervention on the primary outcome will be performed within the
following subgroups of subjects by:Age < 75 years, > 75 years.
Sex – male or female.
Stroke/TIA.
Stroke subtype – lacunar, posterior fossa or cortical.
Stroke severity – severe, moderate/mild; NIHSS score of < 10, > 10.
Baseline systolic blood pressure of > 160 mmHg, 140–160 mmHg or < 140 mmHg.
Treatment delay of > 24 hours, < 24 hours.
Patients enrolled into TCD substudy.
Patients enrolled into P-selectin substudy.
Patients on antiplatelet therapy at randomisation – mono, dual.
Aspirin naive versus aspirin.
Heparin – none, unfractionated, low-molecular-weight heparin.
Number of TIAs in the last week.
Thrombolysis – yes, no.
An ABCD2 score of 4, > 4.Protocol version 1.2 to 1.3 (20 December 2011)Investigational medicinal product: aspirin and dipyridamole considered as IMP in addition
to clopidogrel.
Known side effects: adverse reactions and drug interactions added for aspirin and dipyridamole.
Purpose and primary objective: updated to reflect use of either clopidogrel or aspirin/dipyridamole as
guideline therapy owing to updated NICE guidance.30als Library www.journalslibrary.nihr.ac.uk
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Park,Trial duration changed: start-up phase 4 years changed from 3 years.
The main phase will recruit in the order of ≈ 3100 patients (depending on the rate and distribution of
ordinal events) and will last an additional 5 years.Protocol version 1.3 to 1.4 (26 February 2013)Funding source: BHF (start-up phase), NIHR Health Technology Assessment (HTA) programme (main phase).
Investigational medicinal product changed:¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
¢
een’s
ocial
als pro
dress
SouthAspirin loading dose to 300 mg, then 50–150 mg per day. Aspirin may be given in combination
with dipyridamole as Asasantin® (Boehringer Ingelheim) or equivalent changed from loading dose
300 mg, then 75 mg once a day.
Dipyridamole 225 mg to 450 mg daily, including 200 mg modified-release twice daily changed
from 200 mg modified-release twice a day.C
eInclusion criteria:Patients who are on combined therapy of aspirin plus dipyridamole or on monotherapy (e.g. aspirin
alone, clopidogrel alone or dipyridamole alone) are eligible for recruitment changed from Already
on dual anti platelet therapy.
Neuroimaging is essential for ischaemic stroke to exclude intracranial haemorrhage and a non-stroke
diagnosis. If the patient received thrombolysis, a post-thrombolysis/pre-TARDIS scan needs to be
carried out to exclude new thrombolysis-associated bleeding prior to enrolment. Typically, this is
done routinely as ‘standard of care’ but, if it is not done, then it must be done prior to enrolment.
Patients thrombolysed for stroke with full recovery in < 24 hours from the onset of symptoms
are eligible for inclusion as a TIA providing neuroimaging post thrombolysis excludes intracranial
haemorrhage. Changed from Neuroimaging is essential for ischaemic stroke to exclude intracranial
haemorrhage and/or non-stroke diagnosis.Exclusion criteria:Deleted participant has taken clopidogrel or dipyridamole after the index event but prior to
randomisation (aspirin is allowed between ictus onset and randomisation).
Added patients who have not had post thrombolysis neuroimaging.Comparators: the remaining decision is dependent on what the patient could be randomised to,
and the general rule is they cannot have something that may confound the guideline group:aspirin, clopidogrel and dipyridamole versus clopidogrel versus aspirin and dipyridamole – aspirin
only before randomisation (i.e. no clopidogrel or dipyridamole)
aspirin, clopidogrel and dipyridamole versus clopidogrel – aspirin or clopidogrel only before
randomisation (i.e. no dipyridamole)
aspirin, clopidogrel and dipyridamole versus aspirin and dipyridamole – aspirin or dipyridamole only
before randomisation (i.e. no clopidogrel added).Protocol violations:Added patients who do not have a post thrombolysis scan.
An ABCD2 score of < 4, not a crescendo TIA and not on dual antiplatelet therapy or monotherapy
antiplatelets changed from an ABCD2 score of < 4, not a crescendo TIA and not on dual
antiplatelet therapy.
Patient receives > 450 mg of dipyridamole daily changed from patient receives > 400 mg daily
of dipyridamole.Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
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20Sponsor: sponsorship of the trial is undertaken in each participating country. The University of
Nottingham will hold a contract with each sponsor. The University of Nottingham is the trial sponsor in
the UK but not in other countries and will delegate responsibility for the design and conduct of the trial
to the chief investigator via our sponsor/chief investigator agreement. Changed from the University of
Nottingham is the trial sponsor in the UK and will delegate responsibility for design and conduct of the
trial to the chief investigator via our sponsor/chief investigator agreement.
Appendix J: trial inclusion flow chart – already on mono/dual antiplatelet therapy changed from already
on dual antiplatelet therapy.Protocol version 1.4 to 1.5 (28 February 2014)Investigational medicinal product: aspirin (loading dose of 300 mg, then 50–100 mg daily) and
dipyridamole (between 225 mg and 450 mg daily), or guideline antiplatelet therapy (aspirin and
dipyridamole or clopidogrel, doses as above) changed from aspirin (loading dose of 300 mg, then
75 mg daily), and dipyridamole (modified-release 200 mg twice daily).
Study duration: 8 years changed from 5 years.
Inclusion criteria added:¢
¢
¢
¢
¢
¢
¢
JourPositive neuroimaging to support the new ischaemic event with resonance imaging diffusion.
Already on combined dual antiplatelet therapy (aspirin and dipyridamole).nExclusion criteria:Added patients on aspirin and clopidogrel prior to the underlying event.
Removed TCD (as not in main study).Protocol violations:Participant has taken dipyridamole between index event and prior to stroke randomisation, when
clopidogrel is the control treatment.
Participant has taken clopidogrel between index event and prior to stroke randomisation, when
aspirin and dipyridamole is the control treatment changed from participant has taken dipyridamole
or clopidogrel following the index event and prior to stroke randomisation.
Added patient does not receive the correct loading dose.Substudies
Three substudies were funded by the BHF in the TARDIS start-up phase.
Platelet function
Platelet expression of P-selectin was used to monitor antiplatelet effects of the interventions. Blood was
taken from all patients at baseline and day 7, fixed, posted by Royal Mail (Royal Mail Plc, London, UK) to
Nottingham, and the surface platelet expression of P-selectin measured using flow cytometry, with blinding
to patient and treatment identity. The effect of pre-randomisation antiplatelet agents on P-selectin has
been published.97 The effect of randomised antiplatelet agents on P-selectin, and the relationship between
P-selectin and outcomes (recurrence, bleeding) is being analysed. Continuation of this substudy in the main
phase of the TARDIS trial was not funded by the HTA programme but was continued, ad hoc, with local
funding. As a result, platelet function was only assessed in a minority of patients.
Cerebral emboli
The TCD recordings were performed from the middle cerebral artery at baseline and day 2 using Nicolet/
EME TCD systems (Pioneer Medical Devices AG, Berlin, Germany) with a 2 MHz transducer, as we haveals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22480 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 48previously described.98 One-hour recordings were stored digitally and transferred to London for analysis by
Hugh S Markus, as before,43 with blinding to patient and treatment identity. Recording protocols were
similar to those successfully used in the CARESS study.43 Unfortunately, the lack of TCD machines across
UK sites, and lack of incentives for NIHR research staff to perform substudies, meant that few participants
had TCD performed (baseline – 39, day 3–21, with 19 participants at both time points), which was
deemed insufficient to analyse. Continuation of this substudy in the main phase of the TARDIS trial was
not funded by the HTA programme and the substudy was closed for the main phase.
Health economic analyses
These analyses, and the necessary data collection, were not funded by the HTA programme and were
not performed.
Meta-analyses
Our previous meta-analyses of intensity of antiplatelet therapy (dual vs. mono) for acute ischaemic stroke/
TIA45,46 were updated with data from the TARDIS trial, this relating to the binary outcomes of recurrence
and major (including fatal) bleeding.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
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The trial was designed in 2007 and initial funding was confirmed in 2008. The trial commenced recruitment
on 7 April 2009 and enrolment was halted on the advice of the independent DMC on 18 March 2016, after
a total of 3096 participants (out of a planned target of 4100; 75.5%) had been enrolled. Prior to this, the
DMC had met on 12 occasions and recommended trial continuation. The advice to stop was based on a
combination of three observations:
1. the presence of a significant increase in major (including fatal) bleeding in participants randomised to
intensive antiplatelet therapy
2. intensive antiplatelet therapy was associated with a non-significant reduction in the primary outcome,
but not enough to numerically outweigh the increase in bleeding
3. a conditional power analysis suggested that the trial was highly unlikely to demonstrate a significant
difference in the primary outcome.
Once the decision to halt further recruitment had been made, patients randomised to intensive antiplatelet
therapy were telephoned and asked to switch treatment to guideline therapy. The TSC reviewed the same
data as well as additional analyses on 12 April 2016 and additionally noted that there was no difference in
the net balance between benefit and hazard based on the composite of death, stroke, MI and major
bleeding. The TSC stopped recruitment on the basis of futility.Participant flow
The recruitment curve is shown in Figure 1 and shows three phases of recruitment: an initial start-up
phase with very low rate, a vanguard phase funded by British Heart Foundation with an intermediate rate0
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FIGURE 1 Recruitment graph by time. Updated from Bath et al.99 © 2016 World Stroke Organization. This article is
distributed under the terms of the Creative Commons Attribution 3.0 License (http://www.creativecommons.org/
licenses/by/3.0/) which permits any use, reproduction and distribution of the work without further permission
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/
en-us/nam/open-access-at-sage).
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24and a main phase with high rate and funded by the NIHR’s HTA programme. The Consolidated Standards
of Reporting Trials (CONSORT) flow diagram is shown in Figure 2. By 90 days, 54 (1.7%) patients had
died and data were missing from 26 (0.8%) patients. A majority of participants (2955, 95.4%) were
recruited in the UK, with others from Denmark and Georgia (134, 4.3%) and New Zealand (7, 0.2%)
(Table 4). Four sites recruited a far higher proportion of patients than other sites (‘waterfall plot’; Figure 3).Intensive
[n = 1556 (50.3%)]
Baseline form
• In-patient in hospital, n = 28 (1.8%)
• Completed, n = 1556 (100%)
Day 7 follow-up
• Completed, n = 1525 (98.0%)
• Died, n = 6 (0.4%)
• Missing, n = 25 (1.6%)
   • Logistical problem, n = 6 (0.4%)
   • Patient refused, n = 19 (1.2%)
Day 35 follow-up
• Completed, n = 1490 (95.8%)
• Died, n = 14 (0.9%)
• Missing, n = 52 (3.3%)
   • Logistical problem, n = 20 (1.3%)
   • Patient refused, n = 32 (2.1%)
Day 90 follow-up
• Completed, n = 1514 (97.3%)
• Died, n = 26 (1.7%)
• Missing, n = 16 (1.0%)
   • Lost to follow-up, n = 0 (0.0%)
   • No vital status, n = 0 (0.0%)
   • Patient refused, n = 15 (1.0%)
   • Other, n = 1 (0.1%)
Hospital discharge or death form
• Completed, n = 1550 (99.6%)
• Died, n = 6 (0.4%)
Guideline
[n = 1540 (49.7%)]
Baseline form
• In-patient in hospital, n = 30 (1.9%)
• Completed, n = 1540 (100%)
Randomised
(n = 3096)
Day 7 follow-up
• Completed, n = 1502 (97.5%)
• Died, n = 6 (0.4%)
• Missing, n = 32 (2.1%)
   • Logistical problem, n = 14 (0.9%)
   • Patient refused, n = 18 (1.2%)
Day 35 follow-up
• Completed, n = 1483 (96.3%)
• Died, n = 14 (0.9%)
• Missing, n = 43 (2.8%)
   • Logistical problem, n = 16 (1.0%)
   • Patient refused, n = 27 (1.8%)
Day 90 follow-up
• Completed, n = 1502 (97.5%)
• Died, n = 28 (1.8%)
• Missing, n = 10 (0.6%)
   • Lost to follow-up, n = 3 (0.2%)
   • No vital status, n = 5 (0.3%)
   • Patient refused, n = 5 (0.3%)
   • Other, n = 0 (0.0%)
Hospital discharge or death form
• Completed, n = 1529 (99.3%)
• Died, n = 11 (0.7%)
FIGURE 2 The CONSORT flow diagram showing the flow of participants in the trial.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 4 Recruitment by country and number of sites with ordering by recruitment
Countries Number of sites (%) Number of patients (%)
UK 100 (94.3) 2955 (95.4)
Georgia 3 (2.8) 83 (2.7)
Denmark 2 (1.9) 51 (1.6)
New Zealand 1 (0.9) 7 (0.2)
Total 106 (100) 3096 (100)
DOI: 10.3310/hta22480 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 48Baseline data
Table 5 shows the baseline characteristics of study participants, which were well matched except for a
difference in ‘other antiplatelets’ (absolute difference of 0.5%). The mean age was 69.0 (SD 10.1) years and
1945 (62.8%) participants were male. Clinical information at the time of randomisation, and subsequent
investigations, judged the qualifying event to be ischaemic stroke in 2220 participants (71.7%), TIA in
838 participants (27.1%) and non-ischaemic stroke/TIA (mimic) in 38 participants (1.2%). The median time
from ictus to randomisation was 29.3 (IQR 21.8–39.6) hours; 314 (10.1%) and 651 (21.0%) participants0
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FIGURE 3 Recruitment by hospital sites (‘waterfall plot’). Updated from Bath et al.99 © 2016 World Stroke
Organization. This article is distributed under the terms of the Creative Commons Attribution 3.0 License
(http://www.creativecommons.org/licenses/by/3.0/) which permits any use, reproduction and distribution of the
work without further permission provided the original work is attributed as specified on the SAGE and Open
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RESULTS
26TABLE 5 Baseline characteristics at time of randomisation in the TARDIS trialNCharacteristicIHR Journals Library www.journalslibrary.nihr.ac.ukTotal Intensive GuidelineNumber of participants 3096 1556 1540Mean age (years) (mean SD)a 69.0 (10.1) 69.1 (9.9) 68.9 (10.3)Male sex, n (%)a 1945 (62.8) 982 (63.1) 963 (62.5)Geographical region, n (%)bUK 2955 (95.4) 1482 (95.2) 1473 (95.6)Denmark 51 (1.6) 26 (1.7) 25 (1.6)Georgia 83 (2.7) 45 (2.9) 38 (2.5)New Zealand 7 (0.2) 3 (0.2) 4 (0.3)Ethnicity, n (%)White 2939 (94.9) 1489 (95.7) 1450 (94.2)Black 63 (2.0) 27 (1.7) 36 (2.3)East Asian 2 (0.1) 1 (0.1) 1 (0.1)South Asian 46 (1.5) 18 (1.2) 28 (1.8)South East Asian 1 (0.0) 1 (0.1) 0 (0.0)Other Asian 11 (0.4) 7 (0.4) 4 (0.3)Mixed: white and black 9 (0.3) 3 (0.2) 6 (0.4)Mixed: other 2 (0.1) 2 (0.1) 0 (0.0)Other 12 (0.4) 4 (0.3) 8 (0.5)Not stated 11 (0.4) 4 (0.3) 7 (0.5)Dominant hand, right, n (%) 2798 (91.5) 1396 (90.8) 1402 (92.2)Source of referral, n (%)Emergency department 2057 (66.4) 1037 (66.6) 1020 (66.2)Outpatient clinic 130 (4.2) 66 (4.2) 64 (4.2)Ambulance 600 (19.4) 302 (19.4) 298 (19.4)General practitioner 157 (5.1) 72 (4.6) 85 (5.5)Inpatient ward 58 (1.9) 28 (1.8) 30 (1.9)Other 94 (3.0) 51 (3.3) 43 (2.8)mRS score, pre-stroke [/6], median (IQR)a 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)0, n (%) 2604 (84.1) 1308 (84.1) 1296 (84.2)1–2, n (%) 490 (15.8) 247 (15.9) 243 (15.8)3, n (%) 2 (0.1) 1 (0.1) 1 (0.1)Medical history, n (%)
Prior antiplatelet agentsAspirin 816 (26.4) 412 (26.5) 404 (26.2)Aspirin and dipyridamole 85 (2.7) 43 (2.8) 42 (2.7)Clopidogrel 162 (5.2) 89 (5.7) 73 (4.7)Other 17 (0.5) 13 (0.8) 4 (0.3)
DOI: 10.3310/hta22480 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 48TABLE 5 Baseline characteristics at time of randomisation in the TARDIS trial (continued )©
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PCharacteristicQueen’s Printer and Controller of HMSO 2018. This work was produced by Bat
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ournals provided that suitable acknowledgement is made and the reproduction is
e addressed to: NIHR Journals Library, National Institute for Health Research, Eval
ark, Southampton SO16 7NS, UK.Totalh et al. under the terms of a commi
search and study and extracts (or in
not associated with any form of ad
uation, Trials and Studies CoordinatIntensivessioning contract issued by the Secr
deed, the full report) may be includ
vertising. Applications for commerc
ing Centre, Alpha House, UniversityGuidelinePrior heparin 7 (0.2) 2 (0.1) 5 (0.3)Glycoprotein inhibitor 0 (0.0) 0 (0.0) 0 (0.0)Gastroprotection (PrPI/H2RA)
a 803 (25.9) 405 (26.0) 398 (25.8)Hypertension 1824 (58.9) 930 (59.8) 894 (58.1)Antihypertensives 1739 (56.2) 880 (56.6) 859 (55.8)Hyperlipidaemia 1317 (44.3) 655 (43.8) 662 (44.8)Lipid lowering 1381 (44.6) 679 (43.6) 702 (45.6)Diabetes mellitus 590 (19.1) 280 (18.0) 310 (20.1)Insulin 59 (1.9) 32 (2.1) 27 (1.8)Oral agents 347 (11.2) 155 (10.0) 192 (12.5)Both (insulin and oral agents) 79 (2.6) 40 (2.6) 39 (2.5)Neither (insulin or oral agents) 105 (3.4) 53 (3.4) 52 (3.4)AFc 1 (0.0) 0 (0.0) 1 (0.1)Stroke 348 (11.2) 189 (12.1) 159 (10.3)TIA 337 (10.9) 174 (11.2) 163 (10.6)Ischaemic heart disease 403 (13.0) 196 (12.6) 207 (13.4)PAD 70 (2.3) 40 (2.6) 30 (2.0)Family history of young stroke 170 (5.9) 89 (6.2) 81 (5.6)Smoking, current, n (%) 784 (25.7) 404 (26.4) 380 (24.9)Alcohol intake, high (> 21 units per week), n (%) 291 (9.7) 150 (10.0) 141 (9.4)Feeding status, n (%)Normal diet 2874 (92.8) 1444 (92.8) 1430 (92.9)Soft diet 168 (5.4) 84 (5.4) 84 (5.5)Nasogastric tube fed 51 (1.6) 26 (1.7) 25 (1.6)PEG/RIG fed 3 (0.1) 2 (0.1) 1 (0.1)IV/SC fluids 0 (0.0) 0 (0.0) 0 (0.0)Nothing 0 (0.0) 0 (0.0) 0 (0.0)Qualifying event, n (%)bIschaemic stroke 2220 (71.7) 1121 (72.0) 1099 (71.4)TIA 838 (27.1) 413 (26.6) 425 (27.6)Crescendoa,d 155 (20.1) 72 (18.6) 83 (21.6)Dual antiplatelets 36 (4.3) 23 (5.6) 13 (3.1)Non-ischaemic stroke/TIAe 38 (1.2) 22 (1.4) 16 (1.0)Side of lesion, right, n (%) 1428 (51.2) 698 (50.1) 730 (52.3)Weakness, n (%) 2789 (90.1) 1392 (89.5) 1397 (90.8)Sensory loss, n (%) 1066 (34.4) 511 (32.8) 555 (36.0)Dysphasia, n (%) 1007 (32.5) 522 (33.5) 485 (31.5)continuedetary of State for Health
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RESULTS
28TABLE 5 Baseline characteristics at time of randomisation in the TARDIS trial (continued )NCharacteristicIHR Journals Library www.journalslibrary.nihr.ac.ukTotal Intensive GuidelineIsolated, n (%) 160 (5.2) 88 (5.7) 72 (4.7)Neglect, n (%) 331 (10.7) 154 (9.9) 177 (11.5)Hemianopia, n (%) 304 (9.8) 146 (9.4) 158 (10.3)Isolated, n (%) 16 (0.5) 6 (0.4) 10 (0.6)Dysarthria, n (%) 1279 (41.3) 650 (41.8) 629 (40.8)Posterior circulation, n (%) 287 (9.3) 147 (9.4) 140 (9.1)NIHSS score (/42), mean (SD) 2.8 (3.6) 2.9 (3.7) 2.7 (3.5)ABCD2 score [/7], median (IQR)a 5.0 (5.0–6.0) 5.0 (5.0–6.0) 5.0 (5.0–6.0)GCS score [/15], median (IQR) 15.0 (15.0–15.0) 15.0 (15.0–15.0) 15.0 (15.0–15.0)Classification, n (%)aTotal anterior 181 (5.9) 86 (5.5) 95 (6.2)Partial anterior 1412 (45.6) 714 (45.9) 698 (45.4)Lacunar 1288 (41.6) 646 (41.5) 642 (41.7)Posterior 213 (6.9) 110 (7.1) 103 (6.7)TOAST, n (%)fCardioembolicc 134 (4.4) 65 (4.2) 69 (4.5)Large vessel 490 (16.0) 268 (17.5) 222 (14.6)Small vessel 1224 (40.0) 621 (40.5) 603 (39.6)Mixed 22 (0.7) 8 (0.5) 14 (0.9)Other 1182 (38.7) 569 (37.1) 613 (40.2)SBP (mmHg),a mean (SD) 143.5 (18.2) 143.4 (17.8) 143.6 (18.5)DBP (mmHg), mean (SD) 79.5 (11.4) 79.4 (11.3) 79.6 (11.5)Heart rate, mean (b.p.m.), mean (SD) 73.1 (12.6) 72.9 (12.5) 73.2 (12.7)Haemoglobin (g/l), mean (SD) 141.8 (14.7) 141.9 (15.1) 141.6 (14.3)Blood sugar (mmol/l), mean (SD) 6.8 (2.5) 6.8 (2.6) 6.8 (2.5)Temperature (Celsius), mean (SD) 36.5 (0.5) 36.5 (0.5) 36.5 (0.5)Weight (approximate, in kg), mean (SD) 75.3 (16.6) 75.5 (16.7) 75.1 (16.5)Brain imagingNormal/no lesion, n (%) 1550 (50.1) 770 (49.5) 780 (50.7)Ischaemic stroke, n (%) 1390 (45.0) 702 (45.1) 688 (44.8)Non-stroke, n (%) 6 (0.2) 4 (0.3) 2 (0.1)No brain scan, n (%) 146 (4.7) 79 (5.1) 67 (4.4)Time OTR (hours),a median (IQR) 29.3 (21.8–39.6) 29.3 (21.7–39.7) 29.3 (21.9–39.5)Index eventIschaemic stroke, median (IQR) 32.1 (24.7–41.2) 32.2 (24.6–41.7) 32.0 (24.8–41.0)TIA, median (IQR) 24.2 (17.5–29.7) 24.3 (17.5–29.5) 24.2 (17.5–30.0)
DOI: 10.3310/hta22480 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 48were recruited within 12 and 13–24 hours of onset, respectively. In participants recruited with an ischaemic
stroke, the mean NIHSS score was 4.0 (SD 3.8) and 336 participants (15.7%) received thrombolysis. In
participants who were thrombolysed, the median times to this commencing from ictus and randomisation
were 2.3 (IQR 1.8–3.0) hours and 36.5 (IQR 28.4–42.6) hours, respectively. In TIA participants, the median
ABCD2 score was 5.0 (IQR 5.0–6.0), 155 participants (20.1%) presented with a crescendo TIA (defined as
more than one TIA over the previous week), and 36 participants (4.3%) were already taking two antiplatelet
agents. Among all participants, the mean blood pressure was 143.5 (SD 18.2)/79.5 (SD 11.4) mmHg and the
clinical syndrome was cortical (combined total and partial anterior syndromes) in 1593 participants (51.5%)
and lacunar in 1288 participants (41.6%).63Antiplatelet treatment
Out of the 3096 recruited participants, 1556 were randomised to intensive antiplatelet therapy and 1540
to the guideline group (see Figure 2). More participants were randomised to clopidogrel alone (n = 849,
55.1%) than combined aspirin and dipyridamole (n = 691, 44.9%) in the control group. Adherence to
randomised treatment over the first 7 days was fair in both treatment groups: initial treatment was
received in 83.5% of patients and 98.4% received at least some randomised treatment during the first
week (Table 6). Participants randomised to intensive antiplatelets were more likely to receive all treatment
in the first week than those randomised to guideline treatment.
The rate of treatment crossover was low: 6 (0.4%) participants randomised to the intensive group did not
receive triple antiplatelets and 30 (1.9%) participants randomised to the guideline group received intensive
antiplatelets at some point in the treatment phase. During treatment, 37 (1.2%) participants had carotid
endarterectomy leading to temporary cessation of one or more antiplatelets (Table 6). A further 31 (1.0%)
participants had antiplatelet therapy replaced with oral anticoagulation following identification of AF.
Gastroprotection was recommended in the protocol and was provided in 803 (25.9%) patients: intensive
for 405 patients (26.0%) and guideline for 398 patients (25.8%). Following the final DMC review and early
closure to recruitment, participants randomised to intensive antiplatelet therapy were immediately asked to
switch treatment to guideline therapys.TABLE 5 Baseline characteristics at time of randomisation in the TARDIS trial (continued )©
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TABLE 6 Adherence and reasons for non-adherence during the first 7 days
Adherence, n (%) All Intensive Guideline p-value
Participants randomised 3096 1556 1540
Adherence during first 7 days
First treatment 2584 (83.5) 1391 (89.4) 1193 (77.5) < 0.001
Any treatment 3045 (98.4) 1525 (98.0) 1520 (98.7) 0.14
Incomplete treatment by day 7 974 (31.5) 459 (29.5) 515 (33.4) 0.030
Discharged 652 (21.1) 299 (19.2) 353 (22.9) 0.026
Lost to follow-up 51 (1.6) 23 (1.5) 28 (1.8) 0.45
Recurrent stroke/TIA 52 (1.7) 22 (1.4) 30 (1.9) 0.33
Bleeding event 93 (3.0) 57 (3.7) 36 (2.3) 0.032
Adverse event, unacceptable
Headache 27 (0.9) 21 (1.3) 6 (0.4) 0.002
Rash 5 (0.2) 3 (0.2) 2 (0.1) 0.65
SAE 95 (3.1) 50 (3.2) 45 (2.9) 0.63
Death 11 (0.4) 5 (0.3) 6 (0.4) 0.72
Anticoagulation for AF 31 (1.0) 18 (1.2) 13 (0.8) 0.51
Carotid endarterectomy 37 (1.2) 19 (1.2) 18 (1.2) 0.94
Other 185 (6.0) 84 (5.4) 101 (6.6) 0.13
When discharged, participants were given the remaining part of their course of antiplatelet(s) to complete at home.
RESULTS
30Outcome assessment
Final follow-up (at day 90) was completed for 3016 (97.4%) participants and vital status was available for
all but five (0.1%) (see Figure 2). Outcomes were determined by telephone in 2889 (93.3%) participants
and by post in 67 (2.2%) participants.Primary efficacy outcome
The primary outcome (recurrent stroke or TIA and their severity by day 90) was determined in 3070
(99.2%) participants. Overall, a total of 198 (6.4%) participants had a recurrent stroke or TIA (intensive,
n = 93, vs. guideline, n = 105; Table 7), which comprised 118 strokes (ischaemic, n = 96; haemorrhagic,
n = 19; unknown type due to absence of neuroimaging, n = 5; both an ischaemic and haemorrhagic
stroke, n = 1; and both an ischaemic and unknown type of stroke, n = 1) and 80 TIAs. There was no
difference in the incidence and severity of stroke or TIA (acOR 0.90, 95% CI 0.67 to 1.20; p = 0.47) or
fatal stroke (aOR 1.95, 95% CI 0.76 to 4.99; p = 0.16) between intensive and guideline antiplatelet
therapies (Figure 4 and see Table 7). The likelihood ratio test for the proportional odds assumption was
not significant (χ2 = 0.178, degrees of freedom = 8; p = 1.00). The primary efficacy outcome by time to
recruitment is shown in Table 8.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 7 Primary efficacy outcome as assessed at day 90
Outcome All, n (%)
Intensive,
n (%)
Guideline,
n (%)
Adjusted cOR/OR
(95% CI) p-value
Unadjusted
cOR/OR (95% CI) p-value
Number 3096 1556 1540
Primary outcome 3070 1540 1530
Ordinal stroke/TIA 198 (6.4) 93 (6.0) 105 (6.9) 0.90 (0.67 to 1.20) 0.47 0.88 (0.66 to 1.18) 0.39
Death (mRS
score of 6)
20 (0.7) 13 (0.8) 7 (0.5) 1.95 (0.76 to 4.99) 0.16 1.85 (0.74 to 4.66) 0.19
mRS score of 4–5 20 (0.7) 11 (0.7) 9 (0.6)
mRS score of 2–3 45 (1.5) 22 (1.4) 23 (1.5)
mRS score of 0–1 33 (1.1) 15 (1.0) 18 (1.2)
TIAa 80 (2.6) 32 (2.1) 48 (3.1)
No stroke/TIA 2872 (93.6) 1447 (94.0) 1425 (93.1)
Sensitivity analyses
Ordinal, per
protocol
124 (5.9) 65 (6.0) 59 (5.9) 1.07 (0.74 to 1.55) 0.72 1.03 (0.71 to 1.48) 0.89
Recurrent stroke or
TIA
198 (6.4) 93 (6.0) 105 (6.9) 0.88 (0.65 to 1.18) 0.38 0.87 (0.65 to 1.16) 0.35
Recurrent stroke 118 (3.8) 61 (4.0) 57 (3.7) 1.07 (0.74 to 1.56) 0.71 1.07 (0.74 to 1.54) 0.73
Ischaemic 96 (3.1) 46 (3.0) 50 (3.3) 0.91 (0.61 to 1.38) 0.66 0.91 (0.61 to 1.37) 0.65
Haemorrhagic 19 (0.6) 14 (0.9) 5 (0.3) 2.89 (1.02 to 8.19) 0.046 2.80 (1.01 to 7.79) 0.049
Unknown 5 (0.2) 2 (0.1) 3 (0.2) 0.42 (0.04 to 4.61) 0.48 0.66 (0.11 to 3.97) 0.65
mRS score of
> 2
62 (2.0) 34 (2.2) 28 (1.8) 1.23 (0.74 to 2.05) 0.42 1.21 (0.73 to 2.01) 0.46
TIA, alla 88 (2.9) 34 (2.2) 54 (3.5) 0.62 (0.39 to 0.96) 0.033 0.62 (0.40 to 0.95) 0.030
Death 54 (1.7) 26 (1.7) 28 (1.8) 0.88 (0.50 to 1.54) 0.65 0.91 (0.53 to 1.57) 0.75
a When patients had a recurrent stroke and a TIA, the more severe event is counted in the primary outcome.
Comparisons by binary logistic regression or ordinal logistic regression with adjustment for baseline factors. Stroke/TIA is
given by severity; when a patient had more than one event over 90 days, the most severe event is used.
92% 94% 96%
Proportion of participants
98%
Intensive
Guideline
100%
acOR 0.90, 95% CI 0.67 to 1.20; p = 0.47
No recurrent event
TIA
Stroke: mRS score 
of 0–1
Stroke: mRS score 
of 2–3
Stroke: mRS score 
of 4–5
Fatal stroke: mRS 
score of 6
FIGURE 4 Primary outcome as distribution of recurrent stroke and TIA, and their severity, at day 90. Comparison by
ordinal logistic regression adjusted for baseline factors.
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TABLE 8 Primary outcome, by time to randomisation
Outcome
Hours, n (%)
Intensive Guideline
≤ 12 12.1–24 24.1–36 36.1–48 > 48a ≤ 12 12.1–24 24.1–36 36.1–48 > 48a
Number 144 340 537 516 3 166 305 561 494 4
No event, n (%) 131 (91.0) 322 (94.7) 504 (93.9) 488 (94.6) 2 (66.7) 147 (88.6) 277 (90.8) 531 (94.7) 467 (94.5) 3 (75.0)
TIA, n (%) 3 (2.1) 7 (2.1) 12 (2.2) 9 (1.7) 1 (33.3) 9 (5.4) 13 (4.3) 14 (2.5) 11 (2.2) 1 (25.0)
mRS score of 0, n (%) 3 (2.1) 1 (0.3) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7) 2 (0.4) 0 (0.0) 0 (0.0)
mRS score of 1, n (%) 1 (0.7) 2 (0.6) 4 (0.7) 3 (0.6) 0 (0.0) 2 (1.2) 3 (1.0) 4 (0.7) 5 (1.0) 0 (0.0)
mRS score of 2, n (%) 3 (2.1) 2 (0.6) 4 (0.7) 3 (0.6) 0 (0.0) 2 (1.2) 3 (1.0) 3 (0.5) 3 (0.6) 0 (0.0)
mRS score of 3, n (%) 1 (0.7) 1 (0.3) 4 (0.7) 4 (0.8) 0 (0.0) 3 (1.8) 2 (0.7) 3 (0.5) 4 (0.8) 0 (0.0)
mRS score of 4, n (%) 1 (0.7) 0 (0.0) 4 (0.7) 1 (0.2) 0 (0.0) 1 (0.6) 2 (0.7) 3 (0.5) 2 (0.4) 0 (0.0)
mRS score of 5, n (%) 0 (0.0) 0 (0.0) 2 (0.4) 3 (0.6) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
mRS score of 6, n (%) 1 (0.7) 5 (1.5) 2 (0.4) 5 (1.0) 0 (0.0) 2 (1.2) 2 (0.7) 1 (0.2) 2 (0.4) 0 (0.0)
Total, n (%) 13 (9.0) 18 (5.3) 33 (6.1) 28 (5.4) 1 (33.3) 19 (11.4) 28 (9.2) 30 (5.3) 27 (5.5) 1 (25.0)
a Protocol violation.
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DOI: 10.3310/hta22480 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 48Originally, the trial intended to assess the effect of intervention on a nine-level ordinal outcome for stroke
and TIA, and subsequently a five-level outcome. However, these were felt to be over- or under-granular,
respectively, and the six-level outcome was chosen for the final analysis. Decisions on these changes were
made blinded to treatment assignment. In post hoc analyses, the original outcomes were analysed and
gave comparable results (Table 9).
When assessed in prespecified subgroups (Figure 5), there were no significant interactions between the
primary outcome and treatment. In the intensive arm, there was a tendency for fewer and less severe
strokes/TIAs in participants presenting with a mild stroke, and worse outcomes in participants with a more
severe stroke, but this interaction was not significant (p = 0.070). In a sensitivity analysis, the rate of stroke
or TIA by day 90 did not differ between participants receiving intensive versus guideline antiplatelet
therapy (aOR 0.88, 95% CI 0.65 to 1.18; p = 0.38) (Figure 6 and see Table 7). Similarly, alternative cut-off
points were tested for the measures of severity, onset to randomisation and degree of carotid stenosis.
These post hoc analyses, and the original results, are shown in Table 10; all the interaction tests
remain non-significant.
Although there was no difference between the treatment groups for stroke alone as an outcome, there
was a tendency for more recurrent strokes of haemorrhagic type in the group randomised to intensive
antiplatelet therapy (aOR 2.89, 95% CI 1.02 to 8.19; p = 0.046) (see Table 7). The rates of TIA were lower
in the intensive treatment group (aOR 0.62, 95% CI 0.39 to 0.96; p = 0.033) (Figure 7 and see Table 7).
Analyses based on unadjusted comparisons did not differ qualitatively for the primary outcome.Secondary efficacy outcomes
Hospital-based assessments
Across all patients, there were no differences in death, recurrence, impairment (assessed using the NIHSS)
or neurological deterioration by day 7 (Table 11). However, headache was more common in participants
assigned to the intensive group (all of whom had been randomised to take dipyridamole, a known cause of
headache101) than the guideline group (of whom 44.9% had been randomised to dipyridamole); in a post
hoc analysis, headache only differed when the intensive group was compared with clopidogrel (32, 2.1% vs.
1, 0.1%; p < 0.001) but not when compared with combined aspirin and dipyridamole (32, 2.1% vs. 8,
1.2%; p = 0.63). Qualitatively, the above observations were similar for events by day 35 (see Table 10). There
was no difference in venous thromboembolism at day 35. Similarly, length of stay in hospital and discharge
disposition (comprising return home, discharge to an institution, or death in hospital), did not differ between
the groups.TABLE 9 Post hoc analyses of primary efficacy outcome for 2, 5, 6 and 9 levels
Levels Ordinal or binary stroke/TIA Adjusted cOR/HR (95% CI) p-value Analysis
2 mRS score of 0–6 and TIA/no event 0.87 (0.66 to 1.16) 0.34 Sensitivity
5 mRS score of 6/2–5/0–1/TIA/no event 0.92 (0.67 to 1.27) 0.61 Post hoc
6 mRS score of 6/4–5/2–3/0–1/TIA/no event 0.90 (0.67 to 1.20) 0.47 Primary
9 mRS score of 6/5/4/3/2/1/0/TIA/no event 0.90 (0.67 to 1.20) 0.47 Post hoc
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Graphical region
UK
Other
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≤ 75
> 75
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Index event
Ischaemic stroke
TIA
Clinical syndrome
LACS
POCS
PACS
TACS
NIHSS
≤ 3 or TIA
> 3
ABCD2 in TIA
≤ 5
> 5
Crescendo TIA
No
Yes
Number of antiplatelets at baseline
0
1
≥ 2
Site comparator choicea
Aspirin/dipyridamole
Clopidogrel
Systolic blood pressure (mmHg)
≤ 140
140 – 160
> 160
Time to randomisation (hours)
≤ 12
12 – 24
> 24
Low dose heparin
Yes
No
Thrombolysis
Yes
No
Gastroprotection
Yes
No
Small vessel disease
Yes
No
Old vascular lesions
Yes
No
Ipsilateral carotid stenosis
< 50%
≥ 50%
All patients
n
2931
139
2195
875
1136
1934
2126
944
1282
211
1396
179
2193
877
612
332
2886
184
1995
976
99
1109
1428
1361
1114
595
310
645
2115
6
3064
338
2732
795
2275
1450
1264
1583
1131
2421
394
3070
OR (95% CI)
0.9 (0.7 to 1.2)
0.4 (0.1 to 2.5)
0.8 (0.6 to 1.2)
1.0 (0.6 to 1.7)
0.8 (0.5 to 1.3)
0.9 (0.6 to 1.3)
0.9 (0.6 to 1.3)
0.9 (0.5 to 1.3)
1.0 (0.6 to 1.5)
0.6 (0.2 to 2.3)
0.8 (0.6 to 1.3)
0.9 (0.3 to 2.6)
0.8 (0.5 to 1.1)
1.4 (0.8 to 2.5)
0.9 (0.5 to 1.7)
0.8 (0.4 to 1.6)
0.9 (0.7 to 1.2)
0.8 (0.4 to 1.9)
0.8 (0.5 to 1.2)
1.1 (0.7 to 1.8)
0.4 (0.1 to 1.7)
0.7 (0.4 to 1.1)
1.2 (0.8 to 1.9)
0.7 (0.4 to 1.1)
1.0 (0.6 to 1.6)
1.2 (0.7 to 2.1)
0.8 (0.4 to 1.6)
0.6 (0.3 to 1.0)
1.1 (0.8 to 1.6)
NC
0.9 (0.7 to 1.2)
1.1 (0.4 to 2.6)
0.9 (0.6 to 1.2)
0.8 (0.5 to 1.3)
0.9 (0.7 to 1.3)
0.9 (0.6 to 1.3)
0.8 (0.5 to 1.3)
0.8 (0.5 to 1.2)
1.0 (0.6 to 1.6)
0.8 (0.6 to 1.1)
1.0 (0.5 to 1.9)
0.9 (0.7 to 1.2)
Interaction p
0.41
0.53
0.67
0.85
0.92
0.070
0.80
0.89
0.31
0.067
0.32
0.17
NC
0.69
0.56
0.83
0.44
0.70
0.39
0.20 0.50 1.0 2.0 5.0
Favours intensive Favours guideline
FIGURE 5 Primary outcome at day 90 in prespecified subgroups. Unadjusted common odds ratio. a, Depending
on local policy and guidelines, sites were given the option to choose which treatment they would give as the
comparator, that is, aspirin/dipyridamole, clopidogrel alone or either treatment. NC, not calculable.
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FIGURE 6 Kaplan–Meier curve for recurrent stroke or TIA over 90 days. Comparison by Cox proportional regression
adjusted for baseline factors.
TABLE 10 Post hoc analyses of treatment–outcome interactions in predefined subgroups: stroke severity/TIA, onset
to randomisation and degree of carotid stenosis interactions for ordinal stroke/TIA recurrence and ordinal bleeding
Analysis Total number Intensive, n (%) Guideline, n (%) OR (95% CI) p-value Interaction p
Stroke severity
Stroke/TIA (NIHSS score)
Original 0.070
> 3 877 442 (28.7) 435 (28.4) 1.41 (0.78 to 2.54) 0.26
≤ 3 or TIA 2193 1098 (71.3) 1095 (71.6) 0.76 (0.54 to 1.06) 0.10
Post hoc 0.18
> 6 326 179 (11.6) 147 (9.6) 1.38 (0.49 to 3.88) 0.55
4–6 551 263 (17.1) 288 (18.8) 1.45 (0.71 to 2.98) 0.31
≤ 3 or TIA 2193 1098 (71.3) 1095 (71.6) 0.76 (0.54 to 1.06) 0.10
Post hoc 0.53
> 5 435 234 (15.2) 201 (13.1) 1.16 (0.48 to 2.80) 0.75
≤ 5 or TIA 2635 1306 (84.8) 1329 (86.9) 0.86 (0.63 to 1.17) 0.33
Major bleeding (NIHSS score)
Original 0.64
> 3 877 442 (28.7) 435 (28.4) 2.66 (1.77 to 4.01) < 0.0001
≤ 3 or TIA 2195 1099 (71.3) 1096 (71.6) 2.39 (1.86 to 3.07) < 0.0001
Post hoc 0.43
> 6 326 179 (11.6) 147 (9.6) 3.92 (1.75 to 8.77) 0.00089
4–6 551 263 (17.1) 288 (18.8) 2.34 (1.44 to 3.79) 0.00060
≤ 3 or TIA 2195 1099 (71.3) 1096 (71.6) 2.39 (1.86 to 3.07) < 0.0001
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TABLE 10 Post hoc analyses of treatment–outcome interactions in predefined subgroups: stroke severity/TIA, onset
to randomisation and degree of carotid stenosis interactions for ordinal stroke/TIA recurrence and ordinal bleeding
(continued )
Analysis Total number Intensive, n (%) Guideline, n (%) OR (95% CI) p-value Interaction p
Post hoc 0.44
> 5 435 234 (15.2) 201 (13.1) 3.10 (1.61 to 5.96) 0.00071
≤ 5 or TIA 2637 1307 (84.8) 1330 (86.9) 2.40 (1.91 to 3.02) < 0.0001
Time
Stroke/TIA (OTR)
Original (hours) 0.17
> 24 2115 1056 (68.6) 1059 (69.2) 1.09 (0.75 to 1.57) 0.65
12.1–24 645 340 (22.1) 305 (19.9) 0.56 (0.30 to 1.03) 0.063
≤ 12 310 144 (9.4) 166 (10.8) 0.78 (0.37 to 1.64) 0.51
Post hoc (hours) 0.069
> 24 2115 1056 (68.6) 1059 (69.2) 1.09 (0.75 to 1.57) 0.65
≤ 24 955 484 (31.4) 471 (30.8) 0.63 (0.39 to 1.00) 0.052
Major bleeding (OTR)
Original (hours) 0.098
> 24 2116 1057 (68.6) 1059 (69.2) 2.77 (2.14 to 3.58) < 0.0001
12.1–24 646 340 (22.1) 306 (20.0) 2.26 (1.38 to 3.68) 0.0011
≤ 12 310 144 (9.3) 166 (10.8) 1.24 (0.62 to 2.46) 0.54
Post hoc (hours) 0.10
> 24 2116 1057 (68.6) 1059 (69.2) 2.77 (2.14 to 3.58) < 0.0001
≤ 24 956 484 (31.4) 472 (30.8) 1.86 (1.25 to 2.75) 0.0020
Carotid stenosis
Stroke/TIA
Original 0.70
≥ 50% 394 196 (13.9) 198 (14.1) 0.96 (0.48 to 1.91) 0.90
< 50% 2421 1211 (86.1) 1210 (85.9) 0.82 (0.59 to 1.15) 0.25
Post hoc 0.43
> 0% 1440 735 (52.2) 705 (50.1) 0.76 (0.51 to 1.13) 0.17
0% 1375 672 (47.8) 703 (49.9) 0.97 (0.61 to 1.53) 0.88
Major bleeding
Original 0.25
≥ 50% 395 197 (14.0) 198 (14.1) 1.69 (0.98 to 2.91) 0.059
< 50% 2422 1211 (86.0) 1211 (85.9) 2.50 (1.95 to 3.20) < 0.0001
Post hoc 0.42
> 0% 1441 736 (52.3) 705 (50.0) 2.13 (1.58 to 2.87) < 0.0001
0% 1376 672 (47.7) 704 (50.0) 2.61 (1.86 to 3.67) < 0.0001
OTR, onset to randomisation.
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FIGURE 7 Kaplan–Meier curve for recurrent TIA over 90 days. Comparison by Cox proportional regression adjusted
for baseline factors.
TABLE 11 Secondary efficacy outcomes
Outcome Number Intensive Guideline
Adjusted
acOR/aMD/aHR
(95% CI) p-value
Unadjusted
cOR/MD/HR
(95% CI) p-value
Patient 3096 1556 1540
Day 7 3096 1556 1540
Death, n (%) 3096 6 (0.4) 6 (0.4) 0.99 (0.28 to 3.54) 0.99 0.99 (0.32 to 3.08) 0.99
Recurrent stroke
or TIA, n (%)
2753 41 (3.0) 57 (4.2) 0.72 (0.47 to 1.10) 0.12 0.71 (0.47 to 1.06) 0.096
NIHSS score (/42),
mean (SD)
2992 1.9 (4.1) 1.9 (4.1) 0.0 (–0.2 to 0.2) 0.94 0.1 (–0.2 to 0.4) 0.67
ND, n (%)a 3056 26 (1.7) 24 (1.6) 1.08 (0.61 to 1.92) 0.79 1.07 (0.61 to 1.87) 0.82
Headache, n (%) 3072 32 (2.1) 9 (0.6) 4.47 (2.03 to 9.83) < 0.001 3.59 (1.71 to 7.54) < 0.001
Day 35 3084 1550 1534
Death, n (%) 3096 14 (0.9) 14 (0.9) 0.93 (0.41 to 2.08) 0.86 0.99 (0.47 to 2.08) 0.98
Recurrent stroke
or TIA, n (%)
3013 70 (4.6) 83 (5.5) 0.83 (0.60 to 1.16) 0.28 0.83 (0.60 to 1.15) 0.26
NIHSS score (/42),
mean (SD)
2918 1.5 (4.7) 1.5 (4.6) 0.0 (–0.3 to 0.3) 0.83 0.1 (–0.3 to 0.4) 0.65
NDa, n (%) 3016 32 (2.1) 33 (2.2) 0.96 (0.58 to 1.58) 0.87 0.96 (0.59 to 1.58) 0.88
Headache, n (%) 3072 40 (2.6) 12 (0.8) 4.13 (2.09 to 8.15) < 0.001 3.37 (1.76 to 6.46) < 0.001
VTE, n (%) 3070 7 (0.5) 8 (0.5) 0.91 (0.31 to 2.66) 0.87 0.87 (0.31 to 2.40) 0.79
Fatal PE 0 (0.0) 0 (0.0)
PE 4 (0.3) 4 (0.3)
DVT 3 (0.2) 4 (0.3)
None 1533 (99.5) 1522 (99.5)
Hospital discharge 3096 1556 1540
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TABLE 11 Secondary efficacy outcomes (continued )
Outcome Number Intensive Guideline
Adjusted
acOR/aMD/aHR
(95% CI) p-value
Unadjusted
cOR/MD/HR
(95% CI) p-value
Length of stay (days),
mean (SD)
2767 5.4 (11.6) 5.2 (11.1) 0.2 (–0.5 to 0.9) 0.62 0.2 (–0.7 to 1.0) 0.67
Discharge disposition, n (%)
Home, alone 3061 334 (21.7) 342 (22.5) 1.05 (0.90 to 1.22) 0.56 1.07 (0.92 to 1.25) 0.38
Home, spouse/
carer
1079 (70.1) 1068 (70.2)
Carer’s home 8 (0.5) 9 (0.6)
Warden-aided flat 1 (0.1) 2 (0.1)
Residential home 8 (0.5) 6 (0.4)
Nursing home 10 (0.6) 8 (0.5)
Rehabilitation
hospital
82 (5.3) 72 (4.7)
Still an inpatient 12 (0.8) 3 (0.2)
Died in hospital,
n (%)
3061 6 (0.4) 11 (0.7) 0.41 (0.14 to 1.21) 0.11 0.54 (0.20 to 1.45) 0.22
Day 90 3096 1556 1540
Death, n (%) 3091 26 (1.7) 28 (1.8) 0.89 (0.51 to 1.55) 0.69 0.99 (0.57 to 1.70) 0.96
Vascular death,
n (%)
3091 14 (0.9) 10 (0.7) 1.42 (0.62 to 3.24) 0.41 1.38 (0.61 to 3.11) 0.43
MI, n (%) 3070 11 (0.7) 12 (0.8) 0.87 (0.38 to 2.01) 0.74 0.91 (0.40 to 2.06) 0.82
Fatal MI 0 (0.0) 1 (0.1)
Non-fatal MI 4 (0.3) 9 (0.6)
Unstable angina 1 (0.1) 0 (0.0)
Stable angina 6 (0.4) 2 (0.1)
No MI/angina 1529 (99.3) 1518 (99.2)
mRS score, median
(IQR)
3070 1.0 [1.0, 2.0] 1.0 [1.0, 2.0] 0.96 (0.85 to 1.10) 0.58 0.98 (0.87 to 1.12) 0.79
BI,b mean (SD) 2980 92.4 (19.8) 93.2 (18.7) –0.6 (–1.9 to 0.6) 0.30 –0.8 (–2.2 to 0.6) 0.26
BI < 60, n (%) 2980 83 (5.6) 68 (4.6) 1.29 (0.89 to 1.87) 0.18 1.23 (0.89 to 1.71) 0.21
ZDS,b mean (SD) 2506 46.1 (17.0) 46.6 (17.5) –0.4 (–1.6 to 0.9) 0.59 –0.5 (–1.9 to 0.8) 0.46
t-MMSE,b mean
(SD)
2360 18.3 (4.2) 18.3 (4.4) 0.0 (–0.3 to 0.3) 0.94 0.0 (–0.3 to 0.4) 0.98
TICS-M,b mean
(SD)
2389 21.1 (6.2) 21.0 (6.5) 0.0 (–0.5 to 0.5) 0.93 0.0 (–0.5 to 0.5) 0.93
EQ-VAS,b mean
(SD)
2859 72.8 (21.5) 72.0 (22.4) 0.9 (–0.6 to 2.5) 0.23 0.8 (–0.8 to 2.4) 0.34
EQ-5D-3L/HSUV,b
mean (SD)
2991 0.7 (0.3) 0.7 (0.3) 0.0 (0.0 to 0.0) 0.43 0.0 (0.0 to 0.0) 0.63
aHR, adjusted hazard ratio; aMD, adjusted mean difference; MD, mean difference; ND, neurological deterioration;
PE, pulmonary embolism; VTE, venous thromboembolism.
Data are number or mean (SD), and OR, HR or mean difference with 95% CIs. Comparison by binary logistic regression,
Cox proportional hazards regression, ordinal logistic regression, or multiple linear regression. Results are shown adjusted for
baseline factors, and unadjusted.
a Neurological deterioration: decrease in NIHSS score of > 3 points.
b Death= BI –5, ZDS 102.5, t-MMSE –1, TICS-M –1, EQ-5D-3L/HSUV 0 and EQ-VAS –1.
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Across all patients, there was no difference between the treatment groups in outcome at day 90 assessed
as dependency (mRS, Figure 8), disability (BI), mood (Zung Depression Scale), cognition (t-MMSE, telephone
interview cognition status – modified, verbal fluency) or quality of life (EQ-VAS) (see Table 11). Similarly, the
rate of MI did not differ between the treatment groups. Analyses based on unadjusted comparisons did not
differ qualitatively for any of the secondary outcomes (see Table 11).Safety: bleeding
The main safety outcome was the distribution of risk and severity of bleeding (using the ordinal scale of
fatal, major, moderate, mild or no bleed) at day 90; this was shifted to more bleeding and bleeding of
greater severity in participants randomised to intensive antiplatelet therapy (acOR 2.54, 95% CI 2.05 to
3.16; p < 0.001) (Table 12 and Figure 9). When the distribution of bleeding and its severity was assessed
in prespecified subgroups, a statistically significant interaction between bleeding and the site comparator
choice was present (Figure 10). Intensive treatment was associated with more bleeding than guideline
treatment when compared within sites that chose aspirin and dipyridamole as the comparator arm than
when compared within sites that chose clopidogrel alone as the comparator. An interaction was also seen
for patients who received thrombolysis; intensive antiplatelets were associated with higher bleeding rates
in those who received thrombolysis than those who did not. The effect of treatment on ordinal bleeding
by time to recruitment is shown in Table 13.
The rate of severe (fatal or major) bleeding by day 90 was 2.5% in those assigned to intensive antiplatelet
therapy and 1.1% among participants receiving guideline antiplatelets [adjusted hazard ratio (aHR) 2.23,
95% CI 1.26 to 3.96; p = 0.006] (Figure 11 and see Table 13). The rates of bleeding increasingly diverged
between the treatment groups up to the end of treatment at day 30 but not thereafter. Combined fatal
and major intracranial bleeding was increased with intensive antiplatelet therapy (aHR 3.84, 95% CI 1.26
to 11.63; p = 0.018). A non-significant tendency to more fatal or major extracranial bleeding was also seen
with intensive antiplatelets (aHR 1.89, 95% CI 0.96 to 3.71; p = 0.064) (see Table 13).0%
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FIGURE 8 Distribution of mRS in all patients at day 90 comparison, by ordinal logistic regression adjusted for
baseline factors.
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TABLE 12 Safety outcomes
Outcome Intensive, n (%) Guideline, n (%) Adjusted acOR/aHR (95% CI) p-value
Participants with data 1541 1531
Safety, bleeding
Ordinal bleeding 305 (19.8) 139 (9.1) acOR 2.54 (2.05 to 3.16) < 0.001
Fatal74 8 (0.5) 3 (0.2) 3.48 (0.89 to 13.63) 0.074
Major 31 (2.0) 14 (0.9)
Moderate 25 (1.6) 13 (0.8)
Mild 241 (15.6) 109 (7.1)
None 1236 (80.2) 1392 (90.9)
Sensitivity analyses
Fatal or major74 39 (2.5) 17 (1.1) 2.23 (1.25 to 3.96) 0.006
Bleeding
Intracranial bleeding 16 (1.0) 5 (0.3) 3.14 (1.14 to 8.61) 0.026
Intracerebral 13 (0.8) 4 (0.3) 3.26 (1.05 to 10.06) 0.040
Subdural or extradural 2 (0.1) 0 (0.0) NC
Fatal 6 (0.4) 3 (0.2) 2.43 (0.59 to 10.01) 0.22
Major 9 (0.6) 1 (0.1) 8.79 (1.10 to 69.95) 0.040
Fatal or major 15 (1.0) 4 (0.3) 3.84 (1.26 to 11.63) 0.018
Extracranial 293 (19.0) 135 (8.8) 2.37 (1.93 to 2.91) < 0.001
Gastrointestinal 48 (3.1) 34 (2.2) 1.39 (0.89 to 2.16) 0.15
Other 255 (16.5) 104 (6.8) 2.70 (2.14 to 3.39) < 0.001
Fatal 2 (0.1) 0 (0.0) NC
Major 24 (1.6) 13 (0.8) 1.71 (0.86 to 3.38) 0.13
Fatal or major 26 (1.7) 13 (0.8) 1.89 (0.96 to 3.71) 0.064
aHR, adjusted hazard ratio; NC, not calculable.
Data are number (%) and OR or HR with 95% CIs. Comparisons by Cox proportional hazards regression or ordinal logistic
regression with adjustment for baseline factors. Haemorrhage is most severe (not necessarily first) bleed over 90 days. No
subarachnoid haemorrhages occurred.
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FIGURE 9 Distribution of ordinal bleeding at day 90. Comparison by ordinal logistic regression adjusted for
baseline factors.
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FIGURE 10 Ordinal bleeding at day 90 in prespecified subgroups. Unadjusted common odds ratio. a, Depending on
local policy and guidelines, sites were given the option to choose which treatment they would give as the comparator,
that is, aspirin/dipyridamole, clopidogrel alone or either treatment. NC, not calculable.
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TABLE 13 Worst bleed, by time to randomisation
Bleeding
Hours, n (%)
Intensive Guideline
≤ 12 12.1–24 24.1–36 36.1–48 > 48a ≤ 12 12.1–24 24.1–36 36.1–48 > 48a
Number 144 340 537 516 4 166 306 561 494 4
None 125 (86.8) 282 (82.9) 429 (79.9) 403 (78.1) 1 (25.0) 148 (89.2) 280 (91.5) 522 (93.0) 440 (89.1) 4 (100.0)
Minor 14 (9.7) 44 (12.9) 86 (16.0) 92 (17.8) 1 (25.0) 12 (7.2) 20 (6.5) 34 (6.1) 41 (8.3) 0 (0.0)
Moderate 2 (1.4) 6 (1.8) 8 (1.5) 7 (1.4) 2 (50.0) 2 (1.2) 2 (0.7) 3 (0.5) 6 (1.2) 0 (0.0)
Major 2 (1.4) 5 (1.5) 13 (2.4) 11 (2.1) 0 (0.0) 3 (1.8) 3 (1.0) 2 (0.4) 6 (1.2) 0 (0.0)
Fatal 1 (0.7) 3 (0.9) 1 (0.2) 3 (0.6) 0 (0.0) 1 (0.6) 1 (0.3) 0 (0.0) 1 (0.2) 0 (0.0)
Total 19 (13.2) 58 (17.1) 108 (20.1) 113 (21.9) 3 (75.0) 18 (10.8) 26 (8.5) 39 (7.0) 54 (10.9) 0 (0.0)
a Protocol violation.
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FIGURE 11 Kaplan–Meier curve for major bleeding over 90 days. Comparison by Cox proportional regression
adjusted for baseline factors.
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apparent by day 7, and ordinal bleeding, major extracranial bleeding and fatal/major bleeding were
different at day 35 (see Table 13). At day 90, intensive antiplatelet was associated with more, and more
severe, bleeding when assessed as the worst (see Table 13) or first (see Table 12 and Table 14) bleed.
Similarly, intensive antiplatelet therapy was associated, in post hoc analyses, with a higher rate of major
bleeding by day 14 of treatment (Table 15).TABLE 14 Cumulative bleeding at 7, 35 and 90 days
Outcome Number Intensive, n (%) Guideline, n (%)
OR/MD (95% CI),
adjusted p-value
Patients 3072 1541 1531
Day 7 (or discharge)
Bleeding, most severe 3072 149 (9.7) 53 (3.5) 2.91 (2.13 to 3.99) < 0.001
Ordinal 3.05 (2.20 to 4.23) < 0.001
Fatal74 3072 5 (0.3) 2 (0.1) 6.14 (0.79 to 47.67) 0.083
Major 8 (0.5) 7 (0.5)
Moderate 14 (0.9) 2 (0.1)
Mild 122 (7.9) 42 (2.7)
None 1392 (90.3) 1478 (96.5)
sICH 3070 6 (0.4) 4 (0.3) 1.48 (0.39 to 5.58) 0.56
mECB 3070 8 (0.5) 6 (0.4) 1.30 (0.44 to 3.80) 0.64
Haemoglobin (g/dl),
mean (SD), [range]
2912 14.0 (1.5), [8.7–20.0] 14.0 (1.4), [9.4–20.9] MD 0.0 (–0.1 to 0.1) 0.71
Fatal/major bleeding 3072 13 (0.8) 9 (0.6) 1.49 (0.63 to 3.53) 0.37
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TABLE 14 Cumulative bleeding at 7, 35 and 90 days (continued )
Outcome Number Intensive, n (%) Guideline, n (%)
OR/MD (95% CI),
adjusted p-value
Day 35
Bleeding, most severe 3072 277 (18.0) 103 (6.7) 2.88 (2.30 to 3.62) < 0.001
Ordinal 3.11 (2.44 to 3.95) < 0.001
Fatal74 3072 6 (0.4) 2 (0.1) 5.78 (0.92 to 36.17) 0.061
Major 28 (1.8) 10 (0.7)
Moderate 22 (1.4) 10 (0.7)
Mild 221 (14.3) 81 (5.3)
None 1264 (82.0) 1428 (93.3)
sICH 3070 10 (0.6) 4 (0.3) 2.36 (0.72 to 7.69) 0.16
mECB 3070 24 (1.6) 9 (0.6) 2.55 (1.18 to 5.53) 0.018
Haemoglobin (g/dl),
mean (SD), [range]
2806 13.6 (1.6), [6.8–18.5] 13.7 (1.4), [7.8–19.5] MD –0.1 (–0.2 to 0.0) 0.031
Fatal/major bleeding 3072 34 (2.2) 12 (0.8) 2.79 (1.43 to 5.41) 0.003
Day 90
Bleeding, first 3072 305 (19.8) 139 (9.1) 2.40 (1.96 to 2.94) < 0.001
Ordinal 2.54 (2.04 to 3.15) < 0.001
Fatal74 3072 8 (0.5) 3 (0.2) 3.47 (0.89 to 13.62) 0.074
Major 25 (1.6) 14 (0.9)
Moderate 23 (1.5) 13 (0.8)
Mild 249 (16.2) 109 (7.1)
None 1236 (80.2) 1392 (90.9)
Fatal/major bleeding 3072 33 (2.1) 17 (1.1) 1.93 (1.07 to 3.47) 0.029
MD, mean difference; mECB, major extracranial bleed.
Bleeding is given by severity. When a patient had more than one bleed, the most severe bleed is used at each time point;
at day 90 the severity of the first bleed is also given. Data are number (%). Comparison by Cox proportional hazards
regression, ordinal logistic regression, or multiple linear regression, shown as OR or mean difference, with 95% CI. Analyses
are adjusted unless stated.
TABLE 15 Post hoc analyses of major bleeding, by time from start of treatment
Analysis Day Adjusted HR (95% CI) p-value
Post hoc 07 1.49 (0.63 to 3.53) 0.37
Post hoc 14 2.48 (1.14 to 5.41) 0.023
Post hoc 21 2.30 (1.13 to 4.69) 0.021
Post hoc 30 2.71 (1.35 to 5.43) 0.005
Main 90 2.23 (1.25 to 3.96) 0.0063
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There was no evidence of a mortality difference between the treatment groups (Figure 12 and see Table 7).
Excluding primary outcome and bleeding events, the overall incidence of SAEs was similar in the two treatment
groups: intensive 21.7% versus guideline 21.4% (acOR 1.02, 95% CI 0.86 to 1.22; p= 0.80) (Table 16 and
Figure 13); similarly, the rate of fatal SAEs did not differ between the treatment groups (intensive 0.8%,
guideline 1.4%, aHR 0.52, 95% CI 0.25 to 1.05; p = 0.070).0.0
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FIGURE 12 Kaplan–Meier curve for death over 90 days. Comparison by Cox proportional regression adjusted for
baseline factors.
TABLE 16 Participants with at least one SAE (excluding bleeding and primary outcome events), by timing, severity
and site
Cause
All, n (%) Fatal, n (%)
Intensive Guideline p-value Intensive Guideline p-value
Severity
SAE (CPHR) 335 (21.7) 327 (21.4) 0.60
Ordinal 0.69
Fatal 13 (0.8) 22 (1.4) 0.13 13 (0.8) 22 (1.4) 0.13
Severe 54 (3.5) 39 (2.5)
Moderate 167 (10.8) 148 (9.7)
Mild 101 (6.5) 118 (7.7)
None 1208 (78.4) 1204 (78.7)
Site
Neurological 106 (6.9) 84 (5.5) 0.11 3 (0.2) 7 (0.5) 0.22
Initial stroke
Complication 3 (0.2) 5 (0.3) 0.48 0 (0.0) 3 (0.2) NC
Extension 26 (1.7) 20 (1.3) 0.39 1 (0.1) 1 (0.1) 1.00
Cardiac 82 (5.3) 84 (5.5) 0.84 2 (0.1) 2 (0.1) 0.99
AF 52 (3.4) 64 (4.2) 0.24 0 (0.0) 1 (0.1) NC
continued
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TABLE 16 Participants with at least one SAE (excluding bleeding and primary outcome events), by timing, severity
and site (continued )
Cause
All, n (%) Fatal, n (%)
Intensive Guideline p-value Intensive Guideline p-value
Failure 5 (0.3) 2 (0.1) 0.28
Hypertension 3 (0.2) 3 (0.2) 0.99
Hypotension 4 (0.3) 7 (0.5) 0.37
Sudden death 2 (0.1) 0 (0.0) NC 2 (0.1) 0 (0.0) NC
Gastrointestinal 43 (2.8) 15 (1.0) 0.00042 2 (0.1) 1 (0.1) 0.57
Respiratory 32 (2.1) 38 (2.5) 0.45 2 (0.1) 3 (0.2) 0.65
Pneumonia 16 (1.0) 8 (0.5) 0.11 1 (0.1) 2 (0.1) 0.57
PE 5 (0.3) 7 (0.5) 0.56 1 (0.1) 0 (0.0) NC
Other 131 (8.5) 158 (10.3) 0.083 4 (0.3) 9 (0.6) 0.17
Unattended death 1 (0.1) 0 (0.0) NC 1 (0.1) 0 (0.0) NC
DVT 7 (0.5) 4 (0.3) 0.38
Malignancy 8 (0.5) 13 (0.8) 0.27 2 (0.1) 7 (0.5) 0.12
Septicaemia 0 (0.0) 1 (0.1) NC 0 (0.0) 1 (0.1) NC
UTI 12 (0.8) 13 (0.8) 0.83
Renal failure 2 (0.1) 2 (0.1) 0.99
Other 11 (0.7) 15 (1.0) 0.42
Timing
By day 7 191 (12.4) 150 (9.8) 0.022 2 (0.1) 4 (0.3) 0.42
By day 35 278 (18.0) 255 (16.7) 0.32 7 (0.5) 10 (0.7) 0.46
By day 90 335 (21.7) 327 (21.4) 0.81 13 (0.8) 22 (1.4) 0.13
CPHR, Cox proportional hazards regression; NC, not calculated; PE, pulmonary embolism; UTI, urinary tract infection.
Comparisons by unadjusted Cox proportional hazards, ordinal and binary logistic regression.
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FIGURE 13 Distribution of SAEs at day 90. Comparison by ordinal logistic regression adjusted for baseline factors.
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(see Table 16). When assessed by time in trial, SAEs were more common by day 7 in the intensive group than
in the guideline group, although this difference had disappeared by day 35 (Figure 14). When considered by
organ, no differences were apparent except that gastrointestinal-based SAEs (excluding reported bleeding
events) were more frequent in the intensive than guideline group despite gastroprotection being recommended
(2.8% vs. 1.0%; p< 0.001; see Table 16). In a post hoc analysis, gastrointestinal-based SAEs (excluding
reported bleeding events) differed for both comparisons of the intensive group with clopidogrel [43 (2.8%)
vs. 8 (0.9%); p= 0.005] and with combined aspirin and dipyridamole [43 (2.8%) vs. 7 (1.0%); p= 0.012],
suggesting that the presence of dipyridamole was not the only explanation for the increase in SAEs.Composite outcomes
The composite end point of any stroke or fatal and major bleeding occurred in 87 (5.6%) participants in
the intensive group and 69 (4.5%) participants in the guideline group (aHR, 1.24, 95% CI 0.90 to 1.70;
p = 0.19) (Table 17). Similarly, the composite end point of death, stroke, MI or fatal and major bleeding
did not differ between the treatment groups: intensive group 102 (6.6%) vs. guideline group 98 (6.4%)
(aHR, 1.02, 95% CI 0.77 to 1.35; p = 0.88). Figure 15 shows a bar chart of the relative frequencies of
different measures of net benefit and risk; no differences are apparent.0.0
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FIGURE 14 Kaplan–Meier curve for SAEs over 90 days. Comparison by Cox proportional regression adjusted for
baseline factors.
TABLE 17 Net benefit: risk at day 90
Outcome Intensive, n (%) Guideline, n (%) Adjusted aHR (95% CI) p-value
Participants 1556 1540
Death 26 (1.7) 28 (1.8) 0.89 (0.51 to 1.55) 0.69
Stroke or major bleed 87 (5.6) 69 (4.5) 1.24 (0.90 to 1.70) 0.19
Stroke, TIA, ACS or death 111 (7.2) 134 (8.8) 0.82 (0.64 to 1.06) 0.14
Vascular death, stroke, MI or major bleed 94 (6.1) 81 (5.3) 1.14 (0.84 to 1.53) 0.40
Death, stroke or MI 79 (5.1) 86 (5.6) 0.91 (0.67 to 1.24) 0.55
Death, stroke, MI or major bleed 102 (6.6) 98 (6.4) 1.02 (0.77 to 1.35) 0.88
Data are number (%) and aHR with 95% CIs. Comparisons by Cox proportional hazards regression with adjustment for
baseline factors. Bleeding is most severe, not first, occurring over 90 days. No subarachnoid haemorrhages occurred.
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48Protocol violations
One or more protocol violations were present in 414 (13.4%) participants, with more present in the intensive
(n= 246, 15.8%) than guideline (n = 154, 10.0%) group (p < 0.001) (Table 18). When considered as subtypes
of violations, the difference between the treatment groups was maintained for matters of trial practice such as
not administering the intervention loading dose or not giving the interventions for at least 16 days.TABLE 18 Protocol violations
Protocol violation All, n (%)
Intensive,
n (%)
Guideline,
n (%) p-value
Patients 3096 1556 1540
Total number of patients with violations 411 (13.3) 244 (15.7) 167 (10.8) < 0.001
Total number of violations 476 290 186
Baseline characteristics – patients 52 (10.9) 28 (9.7) 24 (12.9) 0.27
Randomisation > 48 hours from onset of symptoms 7 (1.5) 4 (1.4) 3 (1.6)
Failure to obtain appropriate consent prior to randomisation 6 (1.3) 3 (1.0) 3 (1.6)
Pre-morbid dependency (mRS) score of > 2 2 (0.4) 1 (0.3) 1 (0.5)
On anticoagulation therapy except low dose low-molecular-
weight heparin
1 (0.2) 1 (0.3) 0 (0.0)
Participant received inappropriate antiplatelet treatment prior to
randomisation
23 (4.8) 12 (4.1) 11 (5.9)
Thrombolysis < 24 hours prior to randomisation 1 (0.2) 0 (0.0) 1 (0.5)
Presumed cardioembolic stroke or history of AF 6 (1.3) 4 (1.4) 2 (1.1)
Concomitant STEMI or NSTEMI 1 (0.2) 1 (0.3) 0 (0.0)
Baseline SBP reading of > 185 mmHg or DBP of > 110 mmHg 2 (0.4) 1 (0.3) 1 (0.5)
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TABLE 18 Protocol violations (continued )
Protocol violation All, n (%)
Intensive,
n (%)
Guideline,
n (%) p-value
Planned surgery within the 90-day follow-up period 1 (0.2) 1 (0.3) 0 (0.0)
Known history of dementia 1 (0.2) 0 (0.0) 1 (0.5)
Unavailable for follow-ups 1 (0.2) 0 (0.0) 1 (0.5)
Baseline characteristics (stroke) – patients 4 (0.8) 2 (0.7) 2 (1.1) 0.65
No cranial imaging results available prior to randomisation 3 (0.6) 2 (0.7) 1 (0.5)
Isolated sensory symptoms, vertigo or dizziness or facial weakness
as presenting symptoms of the index event
1 (0.2) 0 (0.0) 1 (0.5)
Baseline characteristics (TIA) – patients 10 (2.1) 3 (1.0) 7 (3.8) 0.043
Limb weakness and/or dysphasia lasting < 10 minutes 3 (0.6) 1 (0.3) 2 (1.1)
ABCD2 score of < 4, not a crescendo TIA and not on dual
antiplatelet therapy
7 (1.5) 2 (0.7) 5 (2.7)
Practice during the trial – patients 343 (72.1) 221 (76.2) 122 (65.6) 0.012
Subsequent randomisation into another drug or devices trial 1 (0.2) 1 (0.3) 0 (0.0)
Patient has received treatment that they are not randomised to 40 (8.4) 8 (2.8) 32 (17.2)
Failure to complete SAEs when appropriate 1 (0.2) 0 (0.0) 1 (0.5)
Failure to complete outcomes when appropriate 2 (0.4) 0 (0.0) 2 (1.1)
Patient does not receive correct loading dose 116 (24.4) 76 (26.2) 40 (21.5)
Patient receives high dose of treatment post loading 6 (1.3) 3 (1.0) 3 (1.6)
Patient does not receive 5 days of randomised treatment in the
first 7 days
138 (29.0) 101 (34.8) 37 (19.9)
Patient does not receive 16 days of randomised treatment in the
first 21 days
37 (7.8) 28 (9.7) 9 (4.8)
Patient received more than 28 days of randomised treatment 5 (1.1) 4 (1.4) 1 (0.5)
Full consent was not obtained – proxy consent was given prior to
randomisation
3 (0.6) 3 (1.0) 0 (0.0)
Follow-up assessments performed 55 (11.6) 31 (10.7) 24 (12.9) 0.46
Day 7 follow-up or FBC not done on correct date 24 (5.0) 14 (4.8) 10 (5.4)
Day 35 follow-up or FBC not done on correct date 31 (6.5) 17 (5.9) 14 (7.5)
Miscellaneous 6 (1.3) 2 (0.7) 4 (2.2) 0.16
Other protocol violations 6 (1.3) 2 (0.7) 4 (2.2)
DBP, diastolic blood pressure; FBC, full blood count; SBP, systolic blood pressure.
DOI: 10.3310/hta22480 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 48The TARDIS trial in context of earlier antiplatelet intensity trials
Findings from earlier large trials and meta-analyses suggested that acute dual antiplatelet therapy (either
aspirin and dipyridamole, or aspirin and clopidogrel) was superior to one agent in preventing early
recurrent cerebral ischaemic events.45,46 The results of the TARDIS trial, which involved combined aspirin,
clopidogrel and dipyridamole, are statistically different (p = 0.02; I2 80.5%) from those earlier trials that
involved two agents when considering the outcome of recurrent stroke (Figure 16). As a result, the
summary statistic at the bottom of the figure is irrelevant. In contrast, there was no difference between
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FIGURE 16 Recurrent stroke in trials of intensive vs. less intensive antiplatelet therapy in patients with acute (within ≤ 3 days) ischaemic stroke or TIA. Data are updated with
permission from Wong et al.46 (© 2013 American Heart Association, Inc.) and Table 1. M–H, Mantel–Haenszel.
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FIGURE 17 Major bleeding in trials of intensive vs. less intensive antiplatelet therapy in patients with acute (within ≤ 3 days) ischaemic stroke or TIA. Data are updated with
permission from Wong et al.46 (© 2013 American Heart Association, Inc.) and Table 1. M–H, Mantel–Haenszel.
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DOI: 10.3310/hta22480 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 48Chapter 4 DiscussionInterpretation
The TARDIS trial met its main objective of comparing the safety and efficacy of intensive triple antiplatelet
therapy with guideline-based treatment. In this group of patients with acute non-cardioembolic ischaemic
stroke or TIA, intensive antiplatelet therapy did not reduce stroke recurrence or its severity when compared
with guideline antiplatelet therapy. Guideline antiplatelet therapy comprised either clopidogrel alone or
combined aspirin and dipyridamole. Furthermore, intensive antiplatelet therapy did not improve measures
of disability, cognition, quality of life or mood. However, intensive antiplatelet therapy was associated with
both an increase in, and more severe, bleeding. There was no difference in mortality or the composite end
point of stroke or major bleeding.
Previous meta-analyses of trials of antiplatelets in acute stroke/TIA have suggested that it is the number
of drugs (i.e. two vs. one), rather than which drugs are used, that is important when determining efficacy,
at least when considering aspirin, clopidogrel and dipyridamole.45,46 If two agents are better than one, then
three might be better still, providing that bleeding is not overly increased. However, the TARDIS trial
demonstrated that the addition of a third agent does not reduce recurrent stroke but does increase
bleeding. Because the primary outcome included haemorrhagic stroke, the failure to reduce stroke
recurrence and its severity overall appears to reflect the combination of increased secondary intracranial
haemorrhage and a tendency to reduced cerebral ischaemic stroke. Several factors appear to explain the
results. First, participants with a severe stroke (presenting with cortical strokes) tended to do better on
guideline therapy whereas intensive antiplatelets favoured those with mild stroke. The explanation for
this observation is not obvious, as stroke severity did not appear to influence the effect of treatment on
bleeding. Second, the type of guideline comparator appeared to be important, as there was a tendency,
albeit just non-significant, for intensive therapy to have beneficial effects on the primary outcome in
comparison with combined aspirin and dipyridamole, but not when compared with clopidogrel alone. In
parallel, intensive antiplatelet therapy was more likely to cause bleeding when compared with combined
aspirin and dipyridamole than when compared with clopidogrel. Nevertheless, these comparisons are
indirect as most sites did not elect to randomise participants between the guideline groups.
A confounding factor was the use of thrombolysis that may have increased the difference in bleeding
between intensive versus guideline antiplatelet therapy. Large trials such as CHANCE and Acute Stroke
or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES)
excluded patients who received thrombolysis because of shorter recruitment time windows and inclusion
of patients with only mild stroke.47,104 In the TARDIS trial, randomised antiplatelet therapy commenced
24 hours after the completion of any alteplase maintenance dose, which might have promoted bleeding.
A treatment–thrombolysis interaction was present for bleeding, which is surprising as the circulating half-
life of alteplase is a few minutes (although the tissue and biological half-lives may be longer). Furthermore,
antiplatelet agents were given with a loading dose following thrombolysis, as recommended in guidelines,
and it is possible that this acceleration of antiplatelet activity contributed to the risk of bleeding in the
presence of recent thrombolysis. Whatever the reason, this finding suggests that bleeding risk is higher
following intravenous thrombolysis in spite of an interval of ≥ 24 hours between completing alteplase and
randomising into the TARDIS trial.
The TARDIS trial was the first trial designed to use ordered categorical primary and safety outcomes of the
type fatal event/severe non-fatal event/mild non-fatal event/no event. Empirical analyses of this approach
using published data from existing trials of antiplatelets and other prophylactic interventions suggested
that studies would have more statistical power, or the same power for a smaller sample size.76 A key
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54analyses based on binary outcomes. As the primary efficacy analysis was non-significant, the relative
merits of ordinal versus binary analysis could not be adequately assessed for stroke. However, ordinal
bleeding gave comparable, if not more pronounced, results in comparison with the outcome of ‘fatal
or major bleeding’.Strengths
The present trial has several strengths, especially generalisability owing to wide inclusion criteria. In addition
to motor presentations, patients with acute ischaemic stroke included those with severe stroke, dysphasia
or neuroimaging-positive hemianopia. Similarly, patients with TIA included those with crescendo TIA or who
were already on dual antiplatelet agents. Hence, groups of patients who are typically excluded in stroke
prevention trials could be enrolled. Inclusion of patients with severe stroke meant that those with cortical
syndromes, often a minority in such trials, could participate. The wide time window of 48 hours meant that
patients could be enrolled after intravenous thrombolysis. Furthermore, the trial had a large sample size
of > 3000 patients, concealment of treatment assignment, prospective assessment of multiple outcomes
including safety measures such as haemorrhage, very high rates of follow-up (99.2% of participants had
their primary outcome determined), care in specialist stroke services, and use of locally sourced aspirin,
clopidogrel and dipyridamole from a variety of manufacturers (thus increasing the external validity of the
trial). An additional strength is that the results define clearly that three agents do not add further efficacy
over and above standard care based on one or two agents.Limitations
Nevertheless, several limitations apply. First, the broad population might have included groups that were
more likely to either respond (e.g. those with minor stroke or TIA, or atherosclerotic disease105) or have a
major bleed (e.g. those receiving thrombolysis or having small vessel disease or microbleeds106), and this might
explain the neutral results. Future trials of antiplatelets may need to be more specific and focus on individuals
with atherosclerotic disease, who do not have significant numbers of microbleeds on MRI scanning, and
who are known to respond to the antiplatelet agent(s) under test. Second, the antiplatelet agents were
administered in an open-label design and participants knew which drug(s) they were on. This may have
driven the reporting of known adverse events such as headache with dipyridamole and bleeding with
intensive antiplatelet therapy. In mitigation, outcomes at day 90 were assessed centrally and blinded to
treatment assignment to reduce the potential for bias. Third, the comparator group involved different
antiplatelet agents, a situation reflecting changes in national and international guidelines that added
monotherapy with clopidogrel to the existing recommendation of combined aspirin and dipyridamole. The
PRoFESS mega trial compared these two strategies in 20,332 patients with chronic (not acute) ischaemic
stroke or TIA and found no differential effect on stroke recurrence, although major haemorrhage occurred
more frequently with combined aspirin and dipyridamole.107 It should be noted that the TARDIS trial did
not allow aspirin monotherapy (as shown to be effective for ischaemic stroke in two mega trials36,37) as a
comparator because this was not recommended in UK guidelines for secondary prevention in either 2005 or
2010, largely because both aspirin and dipyridamole, and clopidogrel alone, had previously been shown to be
superior to aspirin alone in three large trials.18,20,21 Fourth, the time window for recruitment was longer than in
other trials such as POINT,48 CHANCE47 and SOCRATES,104 and this led to a lower overall event rate because
the risk of recurrence falls with time, even over the first 48 hours. Fifth, randomised treatments were given for
30 days and this might have been too long in view of the identified haemorrhage risk. Importantly, the risk of
haemorrhage for intensive and guideline antiplatelets diverged from the start of randomised treatment and
was significantly different by 14 days; hence, it is not apparent that a shorter period of intensive antiplatelets
would have avoided the risk of bleeding. Last, the trial was stopped early following recommendation by the
independent DMC and the results may represent a false-neutral finding related to the lower than planned
statistical power. The trial recruited > 70% of its planned target of 4100 participants and the post hoc
statistical power remained high at 85%. Furthermore, the prespecified effect size of 0.68 was almost ruledNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22480 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 48out (with 95% confidence). As such, it is likely that the trial’s main findings are correct (i.e. that intensive
antiplatelet therapy does not appear to reduce recurrent cerebral ischaemic events but does increase the
risk of haemorrhage).Patient and public involvement
The trial was designed and delivered with active patient and public involvement (PPI) involvement by three
patients, including in design, helping writing patient information sheets, membership of the TSC and
interpretation of the results.
Attendance at TSCs was challenging for PPI members both in attending physically (in the presence of
continuing physical impairments) and in discussion (in the presence of continuing dysphasia). Although
joining by telephone resolved physical issues it was complicated by partial hearing loss. Nevertheless, these
concerns were outweighed by the active involvement of PPI members, and they enjoyed the experience.Conclusions
Implications for health care
The TARDIS trial showed that among patients with acute ischaemic stroke or TIA who were recruited
within 48 hours after symptom onset, treatment with intensive antiplatelet therapy as compared with
guideline antiplatelet therapy did not reduce stroke recurrence and its severity but did increase bleeding
and its severity. Hence, there is no evidence to support the use of intensive treatment based on three
standard antiplatelets (aspirin, clopidogrel, dipyridamole).
Recommendations for research
Trials are needed to confirm whether or not dual antiplatelet therapy with aspirin and clopidogrel is
superior to aspirin alone in patients with acute stroke or TIA; the POINT trial48 addresses this question.
Intensive treatment with three antiplatelet agents should only be studied in the context of randomised
controlled trials, although there is no obvious reason for further testing of this approach. Future trials
examining potent antiplatelets should consider whether or not it would be safe to use them with existing
antiplatelets in patients with acute cerebral ischaemia. Future trials need to assess the value of establishing
individual patient responses to different antiplatelet regimes, and better ways of identifying patients at risk
of bleeding complications.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Bath et al. under the terms of a commissioning contract issued by the Secretary of State for Health
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